Magnetically responsive hydrogels and uses thereof
A magnetically responsive hydrogel addresses the inefficacy of current diabetic wound dressings by using PEG and magnetic particles to stimulate cellular responses in a magnetic field, enhancing wound healing and glucose regulation for diabetic foot ulcers.
Patent Information
- Application Number
- PCT/SG2024/050288
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-05
- Filing Date
- 2024-05-02
- Publication Date
- 2024-11-14
AI Technical Summary
Current diabetic wound dressings are ineffective in promoting sustained wound healing due to harsh wound microenvironments, leading to cell exhaustion and recurrence, with a need for improved approaches to manage chronic diabetic wounds.
A magnetically responsive hydrogel composed of polymerized polyethylene glycol (PEG) macromonomeric residues crosslinked with magnetic particles and cell adhesion motifs, encapsulating dermal and epidermal cells, which deforms in a magnetic field to stimulate biological responses such as cell migration, proliferation, and extracellular matrix production.
The hydrogel system enhances wound healing by promoting cell proliferation, ECM deposition, and controlled insulin release, improving wound closure and glucose regulation, offering a non-invasive and effective treatment for diabetic foot ulcers.
Smart Images

Figure SG2024050288_14112024_PF_FP_ABST
Abstract
Description
[0001] Magnetically responsive hydrogels and uses thereof
[0002] Technical Field
[0003] The present invention relates, in general terms, to hydrogels and more specifically to cell-laden magnetically responsive hydrogels.
[0004] Background
[0005] The incidence of diabetes mellitus has reached epidemic levels globally and is showing no sign of slowing down. Based on data from the World Health Organization (WHO), 537 million adults are living with diabetes - an equivalent of 1 diabetic patient in every 10 people. Diabetic wounds are a common chronic complication of diabetes mellitus. For example, diabetic patients have a 15- 25% lifetime risk of diabetic foot ulcers.
[0006] During normal wound healing, the wound tissue undergoes three canonical stages of regeneration, namely, inflammation, tissue formation, and remodelling. In the case of chronic or non-healing diabetic wounds, this process is disrupted and wounds are instead characterised by multiple pathological features, including a high glucose environment, decreased metabolism of skin cells, compromised vessel network, impaired extracellular microenvironment (ECM), and persistent inflammation, all of which disrupt healthy cellular and molecular interactions essential for normal wound healing.
[0007] The therapeutic efficacy of existing diabetic wound dressings is poor, leading to frequent wound recurrence. Cell-based therapy such autologous or allogenic skin grafts has been suggested for treating severe diabetic wounds with no other therapeutic options besides limb amputation. The seeded cells can promote re- epithelialization and release of cytokines and growth factors to accelerate cell recruitment, immunomodulation, ECM reconstruction, and neovascularization, all of which are advantageous for wound healing. However, while cells possess the ability to orchestrate wound repair, their viability and activity can be severely compromised when they are introduced into a harsh wound microenvironment, hence necessitating repeated doses. Biomaterials such as hydrogels can be used to protect cells during delivery and transplantation, but most hydrogels lack a mechanism for regulating the activities of loaded cells to minimize cell exhaustion and senescence, and maximize safety. There is thus an urgent clinical need for more effective approaches to address chronic wounds in diabetic patients.
[0008] It would be desirable to overcome or alleviate at least one of the above- described problems.
[0009] Summary
[0010] Disclosed herein is a magnetically responsive hydrogel for wound healing, comprising : a) a matrix comprising polymerised polyethylene glycol (PEG) macromonomeric residues crosslinked with magnetic particles; b) cell adhesion motifs covalently bonded to the matrix; and c) dermal and epidermal cells encapsulated within the matrix; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm; and wherein the hydrogel is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
[0011] In some embodiments, the PEG macromonomeric residues are derived from macromonomeric units comprising two or more unsaturated functional groups selected from the group consisting of methacrylate, acrylate, methacrylamide, acrylamide, norbornene, vinyl sulphone, allyl, vinyl, alkynyl and propiolate.
[0012] In some embodiments, the PEG macromonomeric units are terminally functionalised with two or more unsaturated functional groups.
[0013] In some embodiments, the PEG macromonomeric units are PEG diacrylate (PEGDA) macromonomeric units.
[0014] In some embodiments, the PEG macomonomeric residues are characterised by an average molecular weight of about 1000 Da to about 3000 Da.
[0015] In some embodiments, the PEG macromonomeric residues are characterised by an average molecular weight of about 2000 Da.
[0016] In some embodiments, the hydrogel comprises about 5% w / w to about 10% w / w of PEG macromonomeric residues relative to the hydrogel.
[0017] In some embodiments, the hydrogel has a Young's modulus of about 0.1 kPa to about 1 kPa.
[0018] In some embodiments, the hydrogel has a thickness of about 0.5 mm to about 3 mm.
[0019] In some embodiments, the magnetic particles are thiol-functionalised magnetic particles.
[0020] In some embodiments, the percentage of surface thiol moieties on each magnetic particle is about 0.1% to about 10%.
[0021] In some embodiments, the percentage of surface thiol moieties on each magnetic particle is about 1%.
[0022] In some embodiments, the concentration of magnetic particles in the hydrogel is about 0.5% w / w to about 2% w / w relative to the hydrogel.
[0023] In some embodiments, the magnetic particles are homogeneously distributed within the hydrogel.
[0024] In some embodiments, the cell adhesion motif comprises a peptide.
[0025] In some embodiments, the cell adhesion motif is Arg-Gly-Asp (RGD).
[0026] In some embodiments, the cell adhesion motif is derived from a cell adhesion motif precursor comprising an acrylate group. In some embodiments, the cell adhesion motif is covalently bonded to the matrix via a C-C bond, C-5 bond, amide bond, or a combination thereof.
[0027] In some embodiments, the cell adhesion motif is present at a concentration of about 0.2% w / w to about 0.6% w / w relative to the hydrogel.
[0028] In one embodiment, the cell adhesion motif is present at a concentration of about 0.4% w / w relative to the hydrogel.
[0029] In some embodiments, the cell adhesion motifs are homogeneously distributed within the hydrogel.
[0030] In some embodiments, the hydrogel comprises about 105to about 107encapsulated cells.
[0031] In some embodiments, the hydrogel comprises about 10sencapsulated cells.
[0032] In some embodiments, the ratio of dermal cells to epidermal cells is about 1: 10 to about 10: 1.
[0033] In some embodiments, the ratio of dermal cells to epidermal cells is about 1 : 1.
[0034] In some embodiments, the hydrogel is a photopolymerised hydrogel.
[0035] In some embodiments, the hydrogel is formed from an injectable liquid precursor.
[0036] In some embodiments, the one or more biological response is selected from the group consisting of cell migration, cell proliferation, cell production of extracellular matrix material, and cell secretion of biomolecules.
[0037] In some embodiments, the one or more biological response is selected from the group consisting of increased cell migration out of the hydrogel, increased cell proliferation, increased production of type I collagen, and increased secretion of vascular endothelial growth factor (VEGF).
[0038] In some embodiments, the hydrogel further comprises one or more encapsulated compounds selected from the group consisting of a cytokine, a hormone, a growth factor, an anti-inflammatory compound and an antimicrobial compound.
[0039] In some embodiments, the hydrogel regulates release of the one or more encapsulated compounds when deformed in the presence of a magnetic field.
[0040] In some embodiments, the magnetically responsive hydrogel further comprises an adhesive dressing which borders the magnetically responsive hydrogel.
[0041] Disclosed herein is a kit for forming a magnetically responsive hydrogel, comprising : a) polyethylene glycol diacrylate (PEGDA) macromonomeric units; b) magnetic particles each functionalised with thiol moieties; c) cell adhesion motif precursors each comprising an acrylate moiety; and d) dermal and epidermal cells; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm.
[0042] Disclosed herein is a liquid precursor of a magnetically responsive hydrogel, comprising : a) polyethylene glycol diacrylate (PEGDA) macromonomeric units; b) magnetic particles each functionalised with thiol moieties; c) cell adhesion motif precursors each comprising an acrylate moiety; and d) dermal and epidermal cells; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm.
[0043] In some embodiments, the kit or liquid precursor further comprises a photoinitiator.
[0044] Disclosed herein is a system for use in wound healing, comprising: a) a magnetically responsive hydrogel as disclosed herein; and b) magnetic means for mechanically deforming the hydrogel.
[0045] In some embodiments, the magnetic means is capable of generating a magnetic field with a maximum magnetic flux density of about 0.1 T to about 1 T.
[0046] In some embodiments, the magnetic means is capable of generating a periodic magnetic field.
[0047] In some embodiments, the magnetic means is capable of generating a periodic magnetic field with a frequency of about 0.1 Hz.
[0048] Disclosed herein is a method for stimulating a biological response in a cell, the method comprising encapsulating the cell in a magnetically responsive hydrogel as disclosed herein, and applying a magnetic field to deform the hydrogel to stimulate one or more biological responses from the encapsulated cells.
[0049] In some embodiments, the cell is a dermal or an epidermal cell.
[0050] In some embodiments the applied magnetic field has a maximum magnetic flux density of about 0.1 T to about 1 T.
[0051] In some embodiments, the applied magnetic field is a periodic magnetic field.
[0052] In some embodiments, the applied magnetic field is a periodic magnetic field with a frequency of about 0.1 Hz.
[0053] Disclosed herein is a method of treating a wound in a subject in need thereof, the method comprising contacting a magnetically responsive hydrogel as disclosed herein with the wound in the subject, and applying a magnetic field to deform the hydrogel to stimulate one or more biological responses from the encapsulated cells.
[0054] In some embodiments, the subject is suffering from diabetes mellitus. In one embodiment, the wound is a skin ulcer.
[0055] In some embodiments, the dermal and epidermal cells are autologous, syngeneic or allogeneic with respect to the subject.
[0056] In some embodiments, the applied magnetic field has a maximum magnetic flux density of about 0.1 T to about 1 T.
[0057] In some embodiments, the applied magnetic field is a periodic magnetic field.
[0058] In some embodiments, the applied magnetic field is a periodic magnetic field with a frequency of about 0.1 Hz.
[0059] In some embodiments, the magnetic field is applied for at least about 2 hours a day.
[0060] In some embodiments, the hydrogel is contacted with the wound for at least about 24 hours.
[0061] Disclosed herein is a magnetically responsive hydrogel as disclosed herein for use in treating a wound in a subject in need thereof, wherein the hydrogel is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
[0062] Disclosed herein is the use of a magnetically responsive hydrogel as disclosed herein in the manufacture of a medicament for treating a wound in a subject in need thereof, wherein the medicament is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
[0063] Brief description of the drawings
[0064] Embodiments of the present invention will now be described, by way of non- limiting example, with reference to the drawings in which: Figure 1. Characterization of PEGDA-RGD-TMP hydrogel. (A) Schematic representation of UV-induced gelation system to covalently link PEGDA macromolecules, RGD-motifs and TMPs. (B) Rheological features of PEGDA- RGD-TMP hydrogel supporting gelation induced by UV photo-crosslinking. Insert: liquid precursor becoming hydrogel after UV irradiation. (C) Flow cytometry analysis showing negligible TMP leakage from hydrogel under mechanical stimulation. (D) M-H curves of PEGDA-RGD-TMP hydrogels at different TMP concentrations via SQUID analysis, showing that hydrogels were magneto-responsive. (E) In vitro degradation and swelling ratio of hydrogel in PBS (pH 7.4) at 37°C, showing excellent stability under physiological condition. Data represents mean ± SD, n = 3. (F) Brightfield images showing uniform TMP (black dot) distribution in the cross-section of PEGDA-RGD-TMP hydrogel, exhibiting great distribution in the hydrogel construct (brown area is magnetic hydrogel). (G) SEM images showing porous PEGDA-RGD-TMP hydrogel structure and microparticles. (H) Representative fluorescent images of human dermal fibroblasts and epidermal keratinocytes in hydrogel with fibroblasts exhibiting spreading morphology. (I) Profile of magnetic force applied to PEGDA-RGD-TMP hydrogel with a dynamic magnetic device, and plot in dash box indicates the force profile with the magnet movement ranging from 20 to 66 mm (measured from hydrogel to magnet). (J) Schematic illustration of hydrogel deformation induced by dynamic magnetic fields and multiphysics modeling of bulk hydrogel deformation when hydrogel-magnet distance is 20 (top) or 66 mm (bottom). (UV: ultraviolet, TMP: thiol-coated magnetic particles, SQUID: superconducting quantum interference device, PBS: phosphate-buffered saline, SEM : scanning electron microscopy)
[0065] Figure 2. (A) Chemical equation of Polyethylene Glycol Diacrylate (PEGDA) synthesis and (B) 1H-NMR of PEGDA synthesis with characteristic peaks. Peak al and a2 indicate the presence of unsaturated bonds on the polymer backbone and successful chemical modification, with high %acrylation (~150%) and %maintenance of unsaturated bonds (~96%).
[0066] Figure 3. Material characterizations of PEGDA-RPG-TMP hydrogel. (A) Graphs of fluorescent intensity of RGD-modified hydrogel. To improve the biocompatibility of hydrogel and cell spreading, RGD motifs were grafted on the PEGDA network by ene reaction, and successful introduction was determined by enhanced fluorescent intensity of RGD fluorescent compound. (B) Photos demonstrating injectability and UV-gelation of PEGDA-RGD-TMP hydrogel. (C) 3D colormap showing tunable stiffness (i.e., Young's Modulus) of hydrogel under different polymer mass concentrations and UV exposure time. The black area represents condition with gelation failure. (D) FTIR characteristic peak of carbon-sulfur bond on PEGDA polymer and PEGDA-TMP hydrogel indicate the occurrence of thiol-ene click reaction. (E) Dynamic light scattering (DLS) particle size measurement and TEM image of the thiol-coated magnetic microparticle (TMP). (F) M-H curve of pure TMP via superconducting quantum interference device (SQUID) analysis. Insert: enlarged M-H curve of TMP. (G) Stress-strain curve under 100 cyclic compressions (0-50% strain) showing excellent elasticity of hydrogel. (H) Excellent stability of PEGDA-RGD-TMP hydrogel under at pH 5.0 and 9.0 for at least 4 weeks. (I) Graph of oxygen levels in the hydrogel under different magneto-induced dynamic mechanical stimulations (MDMS). Data represents mean ± SD, n = 3.
[0067] Figure 4. SEM images and illustration of hydrogel internal scaffold. As the TMP concentrations increased and when used in excess, the hydrogel network became more disorganized with reduced network crosslinking rate and increased pore sizes. Data represents mean ± SD, n = 3.
[0068] Figure 5. 3D modeling of confocal images showing uniform 3D distribution of cells (blue) and TMPs (red) within hydrogel construct, indicating uniform distribution of cell and magnetic particles in the hydrogel construct.
[0069] Figure 6. Biocompatibility of PEGDA-RGD-TMP hydrogel. (A) Live-dead staining of cells encapsulated in hydrogel from 0 to 14 days, indicating low cytotoxicity of PEGDA-RGD-TMP hydrogel. CCK-8 absorbance of (B) human epidermal keratinocytes and (C) human dermal fibroblasts and in the hydrogel constructs. Data represents mean ± SD, n = 3.
[0070] Figure 7. The axial deformation of the magnetic hydrogel at different hydrogel- magnet distances.
[0071] Figure 8. Cell expansion and ECM deposition in PEGDA-RGD-TMP hydrogel under MDMS. (A) Fluorescent images of Ki67 expression with / without MDMS (Blue: nuclei; red : Ki67; green: keratin 14, marker of keratinocytes). (B) MDMS at higher force magnitude increased the expressions of cell proliferation-related (MKI67 and YAP1) and ECM-related (COL1A1 and FN1) in fibroblast. (C-E) Graphs of Ki67 positive rate of human FB under MDMS at different force magnitudes and stimulation durations. The highest Ki67+ % occurred at a stronger force magnitude and after 3 days of stimulation. (F) Fluorescent images of newly synthesized collagen type I by FB with / without MDMS (Blue: nuclei; green: collagen type I). All data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05 and **p <0.01. (MDMS: magneto-induced dynamic mechanical stimulation, FB: fibroblast, KC: keratinocyte).
[0072] Figure 9. Bar plots of Ki67 expression in (A) human fibroblast and (B) keratinocyte with / without magneto-mechanical stimulation in either single or co-culture system. Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
[0073] Figure 10. Mechanical stimulation induced YAP nuclear translocation. (A) Representative fluorescent images and (B) graph of YAP nuclear translocation in human dermal fibroblast and (C) schematic illustration of the YAP pathway. Statistical significance is indicated as *p < 0.05.
[0074] Figure 11. Bar plot of collagen type I fluorescent intensity in hydrogel constructs indicating that longer MDMS induced more collagen production. Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.
[0075] Figure 12. MDMS enhances VEGF production and angiogenesis. (A-B) Bar plots of VEGF concentration in FB / KC co-culture system under different MDMS conditions. (C) Bar plot of VEGF concentration in FB / KC single or co-culture system. (D) Heatmap of transcriptional gene expression levels related to KC proliferation and VEGF secretion. (E) Western blot analysis of Ras / MEK / ERK pathway. (F) Western blot analysis of Ras / MEK / ERK pathway during a stimulation-suspension-restimulation regimen. (G) Schematic illustration of proposed mechanism in which mechanically stimulated fibroblasts enhanced VEGF production by keratinocytes. (H) Bar plot showing that conditioned media from mechanically stimulated co-culture cell system (KC+FB+MDMS) led to the highest HUVEC expansion rate in vitro. (I) Contrast brightfield images monitoring of angiogenic sprouting from fibrin gel beads in 0 and 6 h incubated with conditioned medium under different culture conditions. (J) Single cell level tracking of HUVECs migration toward the chemotactic migration gradient over 6 h. Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05 and **p < 0.01. (VEGF: vascular endothelial growth factor, HUVEC: human umbilical vein endothelial cells, KC: keratinocyte, FB: fibroblast) Figure 13. Western blot analysis and protein level of Ras / MEK / ERK pathway. Data represents mean ± SD, n = 3.
[0076] Figure 14. Box and whisker plots of (A) HUVEC numbers of sprout and (B) sprout lengths per bead at 6 h and (C) representative images of positive control group (+VEGF). All box plots indicate median (middle line), 25th, 75th percentile (box) and the lowest (respectively highest) data point (whiskers). Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001. (VEGF: vascular endothelial growth factor, HUVEC: human umbilical vein endothelial cells, KC: keratinocyte, FB: fibroblast) Figure 15. (A) Brightfield images and (B) bar graph of 24-h HUVEC chemotactic migration toward sample gradient. Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001. (VEGF: vascular endothelial growth factor, HUVEC: human umbilical vein endothelial cells, KC: keratinocyte, FB: fibroblast, MDMS: magneto- induced dynamic mechanical stimulation)
[0077] Figure 16. (A) Brightfield, fluorescent, and Al-analyzed images of 36-h in vitro HUVEC tube formation bioassay incubated by conditioned medium under different culture conditions. (B-C) Bar plots of 36-hour in vitro HUVEC tube formation assay incubated by conditioned medium under different culture conditions. Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05 and **p < 0.01. (VEGF: vascular endothelial growth factor, HUVEC: human umbilical vein endothelial cells, KC: keratinocyte, FB: fibroblast, MDMS: magneto-induced dynamic mechanical stimulation)
[0078] Figure 17. Single-cell RNA sequencing analysis and experimental validations of mechano-sensitive fibroblast subpopulations. (A) UMAP plots (left) of fibroblasts from nondiabetic (n=4; 4680 cells) and diabetic (n=7; 19954 cells) skin biopsies, and bar plot (right) of relative abundances of the fibroblast subpopulations. (B) Heatmap showing the top molecular markers of each fibroblast subpopulation and their expression levels, which can be used to identify / isolate the respective subpopulation. (C) Bar plots illustrating the Gene Set Enrichment Analysis (GSEA) of transcriptomes of fibroblast subpopulations using a curated mechano-transduction gene set. Positive and negative normalized enrichment scores (NES) indicate the overrepresentation of gene set of overexpressed and suppressed genes, respectively. (D) Expression level of CD55 in skin fibroblast subpopulations in nondiabetic and diabetic forearm biopsies. (E) Higher mRNA levels of YAP1, MKI67 and COL1A1 in fibroblast subgroups with different CD55 expression after MDMS, indicating that fibroblasts with high CD55 expression were more mechano-sensitive. (F) Cell number of different CD55 expression subgroups after MDMS, showing that mechano-stimulation could promote better proliferation in fibroblast with high CD55 expression. 'Control' group represents unsorted original cell samples. All data represents mean ± SD, n = 4. Statistical significance is indicated as *p < 0.05 and **p < 0.01.
[0079] Figure 18. Pseudotime analysis of the skin fibroblasts illustrating the developmental trajectories of mesenchymal fibroblast into the secretory- reticular, secretory-papillary and proinflammatory lineages.
[0080] Figure 19. Bar graphs of features of primary human-derived dermal fibroblasts and epidermal keratinocytes including (A) cell proliferation and (B) VEGF production. Under magneto-induced dynamic mechanical stimulation (MDMS), there was an obvious increase in cell number with enhanced YAP and MKI67 expression in cell nuclei. MDMS also enhanced VEGF production in the fibroblast / keratinocyte co-culture. Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05 and **p < 0.01.
[0081] Figure 20. (A) Schematic illustration of accelerated drug release by MDMS through higher interstitial flow from hydrogel network deformation. (B) Multiphysics modeling of insulin concentration and distribution showing that MDMS could induce hydrogel dynamic deformation to promote the release of encapsulated insulin. The maximum insulin concentration was at the center of the hydrogel and insulin concentration gradient was observed as insulin diffused out of the hydrogel. White dashed line: hydrogel outline. (C) Profiles of cumulative insulin release under different MDMS conditions, with stronger MDMS leading to higher insulin release from hydrogel in vitro. (D) In vitro insulin release profile with / without MDMS, indicating the ability to tune drug release kinetics. (E) Plot of diabetic mice blood glucose level treated with insulin-loaded magnetic hydrogel. Stronger MDMS induced greater insulin release, leading to more significant changes in blood glucose levels in vivo. (F) Bar plots of number of FB and KC that migrated out of magnetic hydrogel attributing to MDMS in vitro. (G) Flow cytometry of fluorescently labeled FBs / KCs that migrated from hydrogel to wound site with / without MDMS in a diabetic mice model. Data represents mean ± SD, n = 4. Statistical significance is indicated as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. (MDMS: magneto-induced dynamic mechanical stimulation, FB: fibroblast, KC: keratinocyte)
[0082] Figure 21. Multiphysics modeling of comparisons of the insulin concentrationctn = Cin / Cin,within the magnetic hydrogel when subjected to different hydrogel- magnet distances DO under an external dynamic magnetic field or without the magnetic effect. The magneto-induced dynamic mechanical stimulation (MDMS) accelerates insulin release.
[0083] Figure 22. Retention of loaded insulin in hydrogel under magneto-induced dynamic mechanical stimulation (MDMS) with (A) different magnetic field strengths and (B) magnetic field 'ON / OFF' conditions, where stronger field induced higher release rate and the release profile can be tuned by magnetic field. Data represents mean ± SD, n = 3.
[0084] Figure 23. Accelerated effect of cell migration from hydrogel under dynamic mechano-stimulation. (A) Contrast brightfield images of cell migration out of the hydrogel over 48 h under different culture and stimulation conditions (black circle: cell-loaded magnetic hydrogel, red dashed line: boundary of hydrogel). Bar plots of number of (B) fibroblast (FB) and (C) keratinocyte (KC) which migrated out of the magnetic hydrogel. Data represents mean ± SD, n = 3. Statistical significance is indicated as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
[0085] Figure 24. (A) Flow cytometry gating and data analysis. (B) Negative and positive control of flow cytometry. (C) Bar graph of cell migration from hydrogel to mice wound site under magneto-induced dynamic mechanical stimulation (MDMS). Data represents mean ± SD, n = 4. Statistical significance is indicated as **p < 0.01.
[0086] Figure 25. Evaluation of wound healing in diabetic mice models. (A) Schematic illustration of in vivo study design. (B) Representative images of wound area at various time points, showing better therapeutic effect in '3Day / 20mm' group. The percentage represents wound non-closure rate. (C) Graph of wound closure rate under different treatments. (D) Representative images for hematoxylin & eosin (H&E, wound edges are marked by black dashed line) staining of wound tissues harvested on day 7 and 14 after different treatments, indicating better wound healing and re-epithelization of wound bed in '3Day / 20mm' group. (E) Graph of unhealed wound lengths after 7 / 14-day treatments. (F) Representative images for Masson's trichrome (MT, blue line: normal / healed epidermis, green dashed line: unhealed epidermis, black dot line: wound edge) staining of wound tissues harvested on day 7 and 14 after different treatments, indicating better collagen deposition in wound bed in '3Day / 20mm' group. (G) Graph of collagen density around wound bed after 7 / 14-day treatments. (H) Representative immunofluorescent images of Ki67 on day 7 and a-SMA+ vessel (white arrow) on day 14 in wound bed, and quantification analysis of (I) Ki67 positive rate and (J) mature vessels per unit area. White dashed line represents skin epidermal tissue in wound center and black zone is background. Data represents mean ± SD, n = 6-10. Statistical significance to control group is indicated as *p < 0.05. Figure 26. Graph of bulk tissue fold gene expression analysis of HIF1A indicating there was no hypoxia in the wound bed of each treatment group. Data represents mean ± SD, n = 4. No statistical significance is indicated as n.s.
[0087] Figure 27. Bulk tissue gene expression analysis of genes including tissue regeneration, ECM structural component, remodeling enzyme, growth factor, and inflammatory mediator. Fold-change differences in gene expression levels were displayed in heatmap, each row represents the average gene expression profile for one treatment condition, and each column represents a gene.
[0088] Figure 28. (A) In vitro inflammation test of MO macrophage under hydrogel and external magneto-induced dynamic mechanical stimulation. Data represents mean ± SD, n = 3. (B) In vivo inflammation test of macrophage polarization under different conditions. Data represents mean ± SD, n = 7. Statistical significance is indicated as ****p < 0.0001.
[0089] Figure 29. Representative images of H&E staining of mice heart, liver, spleen, lung, and kidney under different treatments, showing no significant organ toxicity.
[0090] Figure 30. CCK-8 absorbance of primary human-derived dermal fibroblasts and epidermal keratinocytes in hydrogel constructs. No obvious influence was found on fibroblast / keratinocyte in the hydrogel, even with MDMS indicating excellent biocompatibility of the PEGDA-RGD-TMP hydrogel platform. Data represents mean ± SD, n = 3.
[0091] Figure 31. Schematic illustration of PEGDA-RGD-TMP magnetic hydrogel treated by magneto-induced dynamic mechanical stimulation (MDMS) for diabetic wound healing. MDMS can promote re-epithelization, extracellular matrix (ECM) reconstruction, angiogenesis, and provide controlled insulin release. Figure 32. Schematic illustration of insulin release from magneto-responsive hydrogel through an external magneto-induced dynamic mechanical stimulation (MDMS).
[0092] Figure 33. Safety evaluation of hydrogel and magnetic hydrogel on porcine wounds. 2x1 cm excisional wounds were made on the dorsum of a female Landrace cross pig on day 0, and hydrogel and magnetic hydrogel (6 mm in diameter) were implanted on wounds on days 7 and 10. The pig was euthanised on day 15, and the wounds were excised for hematoxylin and eosin (H&E) and immunohistochemistry staining, a) Images of H&E-stained wounds after treatment with hydrogel and magnetic hydrogel. Control wounds were treated with saline. Scale bar: 1 mm. b, c) Immunohistochemistry staining of Iba l + macrophages (b) and quantitative analysis of Iba 1 + macrophages occupied area (c). Scale bar: 100 pm. n = 3. d, e) Immunohistochemistry staining of neutrophil (d) and quantitative analysis of neutrophil occupied area (e). Scale bar: 100 pm. n = 3. f, g) Immunohistochemistry staining of CD3+ T cells (f) and quantitative analysis of CD3+ T cells occupied area (g). Scale bar: 100 pm. n = 3. These data showed that hydrogel and magnetic hydrogel-treated wounds had comparable level of wound length and immune cell infiltration including macrophages, neutrophils, and T cells compared to the control, suggesting that the magnetic hydrogel is safe for use in porcine.
[0093] Detailed description
[0094] For avoidance of any doubt, by the polymer matrix comprising the "polymerised macromonomeric residues" is meant that the specified macromonomers have been polymerised to form the polymer matrix and therefore the polymerised macromonomeric residues make up at least a part of the molecular structure of that polymeric matrix. In the present disclosure, the polymeric matrix presents as at least part of its molecular structure polymerised macromonomeric residues of PEG.
[0095] The present disclosure is predicated on the understanding that medical devices that generate mechanical stimulation are also being tested or used in clinics to improve diabetic wound healing, albeit on a limited scale. One example is topical negative-pressure wound treatment (NPWT) which provides mechanical suction to remove wound fluids and is correlated with improved wound closure. While the primary use of NPWT is to remove wound exudates, recent work suggests that dynamic mechanical loading during NPWT may generate "micro- deformation" forces along the wound margins to induce fibroblast cell division and migration, the secretion of growth factors, and formation of new blood vessel formation. In vitro experiments have confirmed that mechanically stimulated fibroblasts proliferated better and secreted more ECM. Mechanical stimulation also induced collective epithelial cell migration in vitro. These findings suggest that mechanical loading may be used to regulate the behaviour of skin cells. However, while in vitro force application is straightforward, trying to achieve an appropriate level of mechanical loading in vivo can be challenging.
[0096] Without wanting to be bound by theory, the inventors exploited the unique strengths of magnetically-responsive hydrogels, cells, and magneto-induced dynamic mechanical stimulation (MDMS) to create a non-invasive dressing to treat chronic wounds such as diabetic wounds. As an example, they synthesized a magnetically responsive PEGDA-based hydrogel containing cell adhesion RGD (Arg-Gly-Asp) motifs and thiol-coated magnetic particles (TMP). This material is referred to as PEGDA-RGD-TMP (Fig. 1A). Dermal fibroblasts and epidermal keratinocytes are encapsulated in the hydrogel to achieve mechanical regulation of cellular functions. MDMS was found to significantly increase cell proliferation, ECM deposition, neovascularization, and glucose regulation (with controllable release of insulin) to achieve better wound closure effect in an in vitro co-culture system and in vivo mouse model of diabetic wound. This is mediated through mechanical activation of fibroblasts which then stimulated co-encapsulated keratinocytes via the Ras / MEK / ERK pathway. Making use of publicly available single cell RNAseq data, the inventors identified and characterised a mechanosensitive secretory-reticular sub-population of CD55-high fibroblasts whose functions can be controlled with MDMS. This demonstrates that exploiting biomaterials to mechanically modulate specific sub-populations of mechano- sensitive fibroblasts can maximize therapeutic efficacy and safety through an ON / OFF magneto-mechanical switch for wound healing. Collectively, the data support that promise of integrating the advantageous features of biomaterials, cells, and external mechanical stimulation into one single platform to accelerate diabetic wound healing that is also broadly applicable to all other wound types. Moreover, the inventors showed that the magneto-responsive property of the disclosed hydrogel system provides on-demand release of insulin through mechano-induced interstitial flow and network movement, supported by computational multiphysics modeling and experimental data. With this combinatorial technology, most of the pathological factors associated with diabetic wounds may be effectively treated, providing a new "all-in-one" strategy for chronic wound treatment.
[0097] Accordingly, disclosed herein is a magnetically responsive hydrogel for wound healing, comprising : a) a matrix comprising polymerised polyethylene glycol (PEG) macromonomeric residues crosslinked with magnetic particles; b) cell adhesion motifs covalently bonded to the matrix; and c) dermal and epidermal cells encapsulated within the matrix; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm; and wherein the hydrogel is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
[0098] The inventors have designed a magnetically responsive PEG hydrogel as part of a magnetically-induced dynamic mechanical stimulation (MDMS) system to treat chronic diabetic wounds. The encapsulation of magnetic particles makes the hydrogel magnetically responsive. The inventors created an external device for generating a dynamic magnetic field, but any suitable device for generating a magnetic field may be used with the hydrogel. Without wanting to be bound by theory, when the intensity of the magnetic field is increased in the vicinity of the hydrogel, magnetic particles covalently bonded to the PEG network are attracted to each other, resulting in a mechanical compression gradient in the hydrogel network, and vice-versa when the magnetic field is decreased. This dynamic magneto-attraction / release induces a dynamic environment with cyclic mechanical stimulation of encapsulated skin cells, and the force amplitude can be easily tuned by adjusting the intensity of the magnetic field. This may be an easy and convenient approach to regulate cell activity for targeted clinical proposes. Accordingly, the hydrogel deforms when subjected to magnetic stimulation. In this regard, matrix of the hydrogel deforms in response to the magnetic field. As is clear from the description herein, due to the gel nature of the hydrogel having an aqueous medium as the liquid, the deformation of the matrix may or may not result in a visible change in the shape or configuration of the hydrogel. A displacement of the matrix may be offset by a flow of liquid.
[0099] As used herein, the term "encapsulated" refers to a hydrogel component (e.g., a cell or a molecule) which is completely or substantially contained within a hydrogel upon formation of the hydrogel matrix. An encapsulated component may be covalently bonded to the hydrogel matrix or may be free to move or diffuse within and out of the hydrogel.
[0100] The hydrogel may comprise encapsulated dermal fibroblasts and epidermal keratinocytes, two cell types approved for wound treatment by the U.S. Food and Drug Administration (FDA). However, any dermal or epidermal cell type may be used. The inventors have found that certain cell types (e.g., fibroblasts and keratinocytes) are easier to culture when encapsulated in a hydrogel of this disclosure than other cell types (e.g., endothelial cells).
[0101] Without wanting to be bound by theory, magnetic stimulation of the hydrogel may activate mechanotransduction pathways in the cells and modify cell behaviour, leading to improved cell proliferation, cell migration, extracellular matrix deposition, re-epithelialisation, as well as the secretion of cytokines and growth factors to accelerate cell recruitment, immunomodulation, ECM reconstruction, and neovascularization, all of which are advantageous for wound healing.
[0102] The hydrogel may further comprise one or more encapsulated bioactive molecules or pharmaceutical compounds, whose release may also be controlled by magnetically-induced deformation of the hydrogel. Magneto-mechanical stimulation can lead to cyclic hydrogel directional deformation to enhance interstitial flow within the material, and this can improve cell migration and accelerate the loaded insulin release from hydrogel to surrounding environment with higher diffusion and exchange rate. This is helpful to maintain the physiologically normal glucose level and avoid excessive insulin delivery and hypoglycemia. The magnetic tunability of the hydrogel allows for precise control over cell activation and / or drug release, preventing excessive treatment and promoting optimal healing outcomes.
[0103] The hydrogel system may be used to treat diabetic foot ulcers. Unlike other wound treatment options, the combination of the cell-laden PEG hydrogel with external magnetically-induced dynamic mechanical stimulation (MDMS) may provide a non-invasive, contactless, and effective method for in vivo mechano- stimulation to promote wound closure and skin regeneration. Further, the external magnetic field offers remote control over the treatment process, preventing tissue damage while enabling the manipulation of hydrogels implanted in deeper tissues, due to the permeability of the magnetic field. The hydrogel construct can be removed after treatment to minimize granulation growth and hindrance to wound closure. Alternatively, the hydrogel's mechanical performance and in vivo stability may allow for longer-term implantation for disease prevention. The controlled live cell therapy and external regulation of paracrine secretion from the encapsulated cells may provide additional benefits over existing treatments for the field of regenerative medicine.
[0104] Compared to the use of chemo-genetics, optogenetics or acousto-genetics to regulate cell function, all of which require genetic engineering (which has low efficiency when performed in primary fibroblasts) and / or invasive or bulky devices like optical fibres and ultrasound machines, the magnetic hydrogel system disclosed herein can achieve reversible control of cell behaviour without further manipulation of target cells.
[0105] The PEG hydrogel disclosed herein offers various advantages over hydrogels made from other synthetic or natural polymers (e.g., gelatin or hyaluronic acid). The hydrogel is biosafe due to the biocompatibility of PEGDA and the RGD motif (which is a key biofunctional component of ECM). PEG imparts water solubility and desirable viscosity in solution and mechanical properties when formed into a hydrogel. PEG does not degrade in vivo, unlike other polymers such as hyaluronic acid and gelatin, and this allows a PEG hydrogel to maintain its mechanical properties and provide stable and long-lasting support after implantation in a subject. It also prevents leakage or loss of magnetic particles or encapsulated cells following implantation, and further allows the hydrogel to be subjected to multiple rounds of magnetic stimulation without compromising its physical structure. PEG is also non-cell-adhesive, which facilitates easy removal of the hydrogel after treatment, and minimises local tissue disruption and patient discomfort when the hydrogel is removed. PEG diacrylate (PEGDA) is an FDA-approved macromolecule, ensuring its biocompatibility and appropriateness for biomedical applications. In contrast to natural macromolecules like gelatin and hyaluronic acid, PEGDA's well-defined chemical composition enables precise control and programming of its biophysical and chemical properties, allowing for more tailored and effective therapeutic outcomes.
[0106] As used herein, a "macromonomeric unit" is a polymer which has at least one reactive end-group which enables it to act as a monomer molecule in a polymerisation reaction to form a hydrogel. A solution of macromonomeric units is capable of gelling or covalently cross-linking to produce a hydrogel. A mixture of macromonomeric units and other desired reactants and / or components for a hydrogel is referred to herein as a "hydrogel precursor" or "precursor mix". A "macromonomeric residue" is used herein in the context of a hydrogel matrix to refer to a polymerised macromonomeric unit, i.e. a macromonomeric unit which has been crosslinked into a hydrogel matrix. A macromonomeric unit or residue may have a range of average molecular weights, e.g., between about 1000 Da to about 3000 Da.
[0107] A PEG macromonomeric unit or residue may be a co-polymer of PEG with another polyalkylene oxide, e.g., polypropylene oxide. A single PEG macromonomer may comprise two polyalkylene oxides having two distinct average molecular weights. The PEG macromonomeric unit may be linear or branched. For example, the PEG macromonomeric unit may have 2 or more termini or arms, e.g., 2 to 12 termini or arms. Techniques and sources for obtaining linear and multi-armed PEG macromonomeric units and attaching functional groups to them are known in the art. A PEG macromonomeric unit may contain one or more functional groups capable of reacting with functional groups on other PEG macromeric units or with functional groups on one or more other components in a precursor mix to form a hydrogel. The terminal functional groups may be reactive, for example, by free radical or electrophile-nucleophile combination. The groups may be reactive with identical groups (e.g., as in free radical polymerisation of acrylates) or with complementary groups (e.g., as in electrophile-nucleophile reactions or free radical addition reactions between a thiol and a vinyl or alkynyl group). The one or more functional groups on a PEG macromonomeric unit may be the same or of different types, with each type of functional group being a chemically distinct group. Different PEG macromonomeric units may have the same or different types of functional groups. Further, it is understood that a linking group may be used to link the macromonomeric unit to the terminal functional group, e.g., an ester or an amide linking group. PEG macromonomeric units may be derivatised according to known chemical reactions and under standard reaction conditions.
[0108] In some embodiments, the PEG macromonomeric residues are derived from macromonomeric units comprising two or more unsaturated functional groups selected from the group consisting of methacrylate, acrylate, methacrylamide, acrylamide, norbornene, vinyl sulphone, allyl, vinyl, alkynyl and propiolate. The functional group may be selected for its ability to participate in thiol-ene or thiol- yne reactions. In some embodiments the PEG macromonomeric units are difunctional.
[0109] In some embodiments, the PEG macromonomeric units are terminally functionalised with two or more unsaturated functional groups.
[0110] In some embodiments, the PEG macromonomeric units are PEG diacrylate (PEGDA) macromonomeric units. The terminal acrylate groups can react with other acrylate groups via a free radical reaction to form a hydrogel. Alternatively and preferably, the acrylate groups can react with a thiol group on another hydrogel precursor component via free radical addition or base- or nucleophile- catalysed Michael addition to form a hydrogel. One advantage of using acrylate as a functional group is its relatively high reactivity, which can facilitate polymerisation and cross-linking reactions. Acrylate groups also form covalent bonds on polymerisation (e.g., C-C or C-S bonds) that are relatively stable and do not readily undergo hydrolysis or other degradation reactions. This can make acrylate-based PEG polymers more durable and longer-lasting than other PEG- based materials.
[0111] In some embodiments, the PEG macromonomeric units or residues are characterised by an average molecular weight of about 1000 to about 3000 Da. The PEG macromonomeric units may have an average molecular weight of about 1000 Da, about 1500 Da, about 2000 Da, about 2500 Da, or about 3000 Da. In one embodiment, the PEG macromonomeric units have an average molecular weight of about 2000 Da.
[0112] In some embodiments, the hydrogel comprises about 2% w / w to about 15% w / w of PEG macromonomeric residues relative to the hydrogel. The component percentage of PEG macromonomeric residues may be determined based on the dry weight of PEG macromonomeric units used for polymerisation relative to the total hydrogel wet weight. The hydrogel may comprise about 2% w / w to about 5% w / w, about 5% w / w to about 7.5% w / w, about 7.5% w / w to about 10% w / w, about 10% w / w to about 12.5% w / w, or about 12.5% w / w to about 15% w / w PEG macromonomeric units. In some embodiments the hydrogel comprises about 5% w / w to about 10% w / w of PEG macromonomeric units. In one embodiment the hydrogel comprises about 5% w / w PEG macromonomeric units relative to the hydrogel.
[0113] The average molecular weight and proportion of PEG macromonomeric units may be varied depending on the desired network and / or physical properties of the hydrogel, e.g., the desired crosslinking density, pore size or Young's modulus of the hydrogel. In general, use of a lower molecular weight PEG macromonomeric unit and a high proportion of PEG macromonomeric units will give a hydrogel with a smaller pore size and lower Young's modulus.
[0114] The magnetic particles may be ferromagnetic or ferrimagnetic. The particles may comprise one or more of the metals iron, cobalt, nickel, aluminium, copper, manganese, zinc, titanium, samarium, neodymium, yttrium and dysprosium, or an oxide or alloy thereof. In one embodiment, the magnetic particles comprise one or more iron oxides, e.g., Fe2O3, Fe3O4 or Fe2O4.
[0115] The magnetic particles are characterised by a particle size of about 1 pm to about 10 pm. The magnetic particles are thus also referred to herein as magnetic microparticles. The large size of the particles (relative to the size of a dermal or epidermal cell) and their covalent linkage to the PEG matrix may reduce cytotoxicity by preventing the cells from internalising the particles.
[0116] The magnetic particles may have a particle size of about 1 μm, about 1.5 μm, about 2 μm, about 2.5 μm, about 3 μm, about 3.5 μm, about 4 μm, about 4.5 μm, about 5 μm, about 5.5 μm, about 6 μm, about 6.5 μm, about 7 μm, about 7.5 μm, about 8 μm, about 8.5 μm, about 9 μm, about 9.5 μm, or about 10 pm. In one embodiment, the magnetic particles are about 3.5 pm.
[0117] In some embodiments, the magnetic particles are thiol-functionalised magnetic particles. The thiol functional group is preferably present on the surface of the magnetic particles. The functional group on the magnetic particles is selected to allow the particles to be covalently linked to the PEG matrix during the crosslinking reaction. For example, thiol-functionalised magnetic particles can participate in thiol-ene crosslinking with a PEGDA macromonomeric unit. Magnetic particles may be surface-functionalised with thiol moieties using any methods available in the art. One such method is provided in U.S. Patent No. 5,705,628. Alternatively, thiol-functionalised magnetic particles are widely available from chemical vendors, e.g., Sigma-Aldrich and Thermo Fisher Scientific.
[0118] In some embodiments, the percentage of surface thiol moieties on each magnetic particle is about 0.1% to about 10%. The percentage of surface thiol moieties on each magnetic particle may be about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10%. The percentage of surface thiol moieties on each magnetic particle may be at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, or at least 10%. In one embodiment the percentage of surface thiol moieties on each magnetic particle is about 1%.
[0119] The magnetic particles are covalently crosslinked with the hydrogel matrix. Covalent linkage prevents leakage of the particles from the hydrogel and enables the hydrogel to deform under magnetic action, e.g., through the movement of the particles towards a magnetic source.
[0120] The particles serve as points of crosslinking within the hydrogel matrix. The form and dimensions of the hydrogel crosslinking can thus be modulated by varying the number of magnetic particles in the hydrogel. In general, the use of a higher concentration of particles increases the crosslinking density and gives a stiffer gel.
[0121] In some embodiments, the concentration of magnetic particles in the hydrogel is about 0.5% w / w to about 2% w / w relative to the hydrogel. The component percentage of the magnetic particles may be determined based on the dry weight of magnetic particles used for polymerisation relative to the total hydrogel wet weight. The concentration of the magnetic particles may be about 0.5% w / w, about 0.6% w / w, about 0.7% w / w, about 0.8% w / w, about 0.9% w / w, about 1% w / w, about 1.1% w / w, about 1.2% w / w, about 1.3% w / w, about 1.4% w / w, about 1.5% w / w, about 1.6% w / w, about 1.7% w / w, about 1.8% w / w, about 1.9% w / w, or about 2% w / w relative to the hydrogel. The concentration of the magnetic particles may be at least 0.5% w / w, at least 0.6% w / w, at least 0.7% w / w, at least 0.8% w / w, at least 0.9% w / w, or at least 1% w / w. In one embodiment the concentration of magnetic particles is about 0.5% w / w relative to the hydrogel.
[0122] In some embodiments the magnetic particles are homogeneously distributed within the hydrogel. This can be achieved by thoroughly mixing a hydrogel precursor mix containing the magnetic particles just before polymerisation to form the hydrogel. The distribution of magnetic particles in a hydrogel may be determined visually, e.g., using light microscopy.
[0123] In some embodiments, the pore size of the hydrogel is about 50 pm to about 350 pm. The hydrogel is porous which is important for skin cell growth by facilitating diffusion of nutrients and cell migration in the hydrogel material. The hydrogel may have an interconnected porous network similar to ECM structure, which supports cell growth and other cellular activity such as cell movement, cell-cell interaction, and nutrient / oxygen diffusion.
[0124] In some embodiments, the hydrogel is characterised by a crosslinking density of at least about 90%. "Crosslinking density" herein refers to the number of functionalised magnetic particles that are crosslinked into the hydrogel. The crosslinking density may be at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%. In some embodiments, the crosslinking density is about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%. A crosslinking density of 100% means that there are no free or unreacted PEGDA acrylate groups in the hydrogel. An excess quantity of functionalised magnetic particles (e.g., thiol-functionalised magnetic particles) may be used in the hydrogel precursor to ensure that all or substantially all of the PEGDA acrylate groups are reacted during hydrogel formation.
[0125] Various methods known in the art may be used to detect free or unreacted functional groups, such as quantitative spectroscopy or functional group-specific assays. Suitable quantitative spectroscopy techniques include but are not limited to Fourier Transform infrared (FTIR) spectroscopy, real-time FTIR, attenuated total reflectance FTIR (ATR-FTIR), Raman spectroscopy, near- infrared (NIR) spectroscopy, photoacoustic spectroscopy, and NMR spectroscopy. Functional group-specific assays may involve the use of functional group-specific probes or dyes, such as colorimetric or fluorescent compounds, which produce a detectable signal upon reaction with a target functional group. The hydrogel is preferably of a stiffness that would provide adequate support for the cells while allowing even deformation on magnetic stimulation. The stiffness may be chosen to be similar to a tissue of interest (e.g., skin tissue or skin wounds). Without wishing to be bound by theory, having a hydrogel which is a close mechanical match to a tissue of interest can help to prevent or reduce immune responses that can disrupt healing. In some embodiments, the Young's modulus of the hydrogel is about 0.1 kPa to about 10 kPa, preferably about 0.1 kPa to about 3 kPa, most preferably about 0.1 kPa to about 1 kPa. The Young's modulus of the hydrogel may be about 0.1 kPa, about 0.2 kPa, about 0.3 kPa, about 0.4 kPa, about 0.5 kPa, about 0.6 kPa, about 0.7 kPa, about 0.8 kPa, about 0.9 kPa, about 1 kPa, about 1.1 kPa, about 1.2 kPa, about 1.3 kPa, about
[0126] 1.4 kPa, about 1.5 kPa, about 1.6 kPa, about 1.7 kPa, about 1.8 kPa, about 1.9 kPa, about 2 kPa, about 2.5 kPa, about 3 kPa, about 3.5 kPa, about 4 kPa, about
[0127] 4.5 kPa, about 5 kPa, about 5.5 kPa, about 6 kPa, about 6.5 kPa, about 7 kPa, about 7.5 kPa, about 8 kPa, about 8.5 kPa, about 9 kPa, about 9.5 kPa, or about 10 kPa.
[0128] The Young's modulus, also known as the elastic modulus, may be determined using compression or tensile testing. In compression or tensile testing, the hydrogel is subjected to a uniaxial compression or tensile load while the resulting stress and strain are measured. The stress (a) is calculated as the applied force (F) divided by the cross-sectional area of the hydrogel perpendicular to the applied force (A), while the strain (e) is the change in hydrogel thickness (AL) divided by the original thickness of the hydrogel (L). The Young's modulus is the ratio of the stress applied to the strain measured (i.e., o / e, or (FxL) / (AxAL)). The skilled person may also use other methods known in the art to calculate the Young's modulus.
[0129] The extent of crosslinking and the Young's modulus may be modulated through variations in the relative amounts of macromonomer units, magnetic particles, cell adhesion motifs and / or the initiator.
[0130] Thin hydrogels are preferred to allow for even deformation under magnetic stimulation as well as adequate perfusion of the encapsulated cells. In some embodiments, the hydrogel has a thickness of about 0.5 mm to about 3 mm, for example about 0.5 mm, about 1 mm, about 1.5 mm, about 2 mm, about 2.5 mm, or about 3 mm.
[0131] The inclusion of cell adhesion motifs to the PEG hydrogel improves the ability of cells to adhere to and spread within the hydrogel, which is critical for subsequent mechanical stimulation of the cells.
[0132] In some embodiments, the cell adhesion motif comprises a peptide. The peptide may be derived or engineered from the cell attachment motif of an extracellular matrix molecule, e.g., collagen, laminin or fibronectin. Non-limiting examples of peptide sequences include RGD (Arg-Gly-Asp), YIGSRY (Tyr-Ile-Gly-Ser-Arg- Tyr), YIGSR (Tyr-Ile-Gly-Ser-Arg), RGDY (Arg-Gly-Asp- Tyr), REDV (Arg-Glu- Asp-Val), REDVY (Arg-Glu-Asp-Val-Tyr), RGDS (Arg-Gly-Asp-Ser), RGDF (Arg- Gly-Asp-Phe), PDSGR (Pro-Asp-Ser-Gly-Arg), PDSGRY (Gly-Pro-Asp- Ser-Gly- Arg-Tyr), IVAVC (Ile-Lys-Val-Ala-Val-Cys), IKVAV (Ile-Lys-Val-Ala-Val) and IKVAVY (Ile-Lys-Val-Ala-Val-Tyr). The peptide may be linear or cyclic. In preferred embodiments, the cell adhesion motif is Arg-Gly-Asp (RGD).
[0133] In some embodiments, the cell adhesion motif is derived from a cell adhesion motif precursor comprising an acrylate group. The term "cell adhesion motif precursor" is used herein to refer to a molecule containing both the cell adhesion motif and a reactive moiety for covalently linking the cell adhesion motif to the hydrogel matrix. The acrylate group on the cell adhesion motif precursor may react with another acrylate group (e.g., on a PEGDA macromonomeric unit) or with a complementary functional group (e.g., a thiol) in the hydrogel precursor mixture during hydrogel polymerisation.
[0134] In some embodiments, the cell adhesion motif comprises a cysteine residue. The cysteine residue provides a thiol functional group so that the cell adhesion motif may crosslink with the macromonomer units. The cysteine residue may be at an end of the cell adhesion motif thereof.
[0135] In some embodiments, the cell adhesion motif is covalently bonded to the matrix via a C-C bond, C-S bond, amide bond, or a combination thereof. In some embodiments, the cell adhesion motif is present at a concentration of about 0.2% w / w to about 0.6% w / w relative to the hydrogel. The component percentage of the cell adhesion motifs may be determined based on the dry weight of the cell adhesion motif precursor used for polymerisation relative to the total hydrogel wet weight. The cell adhesion motif may be present at a concentration of about 0.2% w / w, about 0.22% w / w, about 0.24% w / w, about 0.26% w / w, about 0.28% w / w, about 0.3% w / w, about 0.32% w / w, about 0.34% w / w, about 0.36% w / w, about 0.38% w / w, about 0.4% w / w about 0.42% w / w, about 0.44% w / w, about 0.46% w / w, about 0.48% w / w, about 0.5% w / w, about 0.52% w / w, about 0.54% w / w, about 0.56% w / w, about 0.58% w / w, or about 0.6% w / w. In one embodiment the cell adhesion motif is present at a concentration of about 0.4% w / w relative to the hydrogel.
[0136] In some embodiments, the hydrogel comprises about 105to about 107encapsulated cells. In one embodiment the hydrogel comprises about 106encapsulated cells.
[0137] In some embodiments, the ratio of dermal cells to epidermal cells is about 1: 10 to about 10: 1. The number and proportion of dermal and epidermal cells may be chosen to produce a desired cellular response when the hydrogel is used for wound healing. For instance, more dermal cells may be incorporated to produce extracellular matrix material on mechanical stimulation. Alternatively, more epidermal cells may be incorporated as these cells are able to secrete bioactive molecules when mechanically stimulated. In one embodiment the ratio of dermal cells to epidermal cells is about 1: 1.
[0138] Epidermal cells that may be used include but are not limited to keratinocytes, melanocytes, Langerhans cells and epidermal stem cells. Dermal cells that may be used include but are not limited to fibroblasts, adipocytes and macrophages. In one embodiment, the epidermal cells are keratinocytes. In one embodiment, the dermal cells are fibroblasts.
[0139] In some embodiments, the dermal and epidermal cells are autologous, syngeneic or allogeneic with respect to a subject to which the hydrogel is to be applied. By "autologous cell" is meant a cell obtained from the subject whose wound is to be treated. By "allogeneic cell" is meant a cell obtained from a donor who is the same species as but a different individual from the subject to be treated. By "syngeneic cell" is meant a cell from a same-species donor who has been histocompatibly matched with the subject to be treated. The cell may be from a cell line.
[0140] Dermal and epidermal cells can be obtained from any tissue or organ, but preferably from the tissue or organ to be treated, e.g., dermal and epidermal cells to be used for treating a skin wound are preferably obtained from the skin of a subject or a donor. The cells may be obtained from a tissue sample, e.g., from a biopsy. Any means known in the art for isolating dermal and epidermal cells from a tissue sample may be used, e.g., enzymatic treatment (for example, but not limited to, treatment with trypsin or type I collagenase), centrifugation, immunocytometry, or culture in supports or media favouring the selective proliferation of dermal and / or epidermal cells. The dermal and epidermal cells may be identified by methods commonly used in the art, e.g., by immunocytochemistry, gene expression assays, cell functional assays or morphological observations.
[0141] The use of autologous cells in the hydrogel allows the hydrogel to be used in vivo for wound healing without the need to suppress the immune system of the subject. However, allogeneic or syngeneic cells from a donor may also be used, e.g., in circumstances when there may not be time or it may not be possible to isolate and culture the required cells from a subject.
[0142] In some embodiments, the dermal and epidermal cells are derived from stem cells, non-limiting examples of which include pluripotent stem cells, induced pluripotent stem cells and mesenchymal stem cells. The stem cells may be autologous, syngeneic, allogenic or xenogeneic with respect to a subject to which the hydrogel is to be applied. Stem cells of xenogeneic origin are obtained from a different species as the subject to be treated.
[0143] Stem cells may be obtained from any tissue or organ from a subject or donor.
[0144] The stem cells can be characterised by means of identifying surface and / or intracellular proteins, genes, and / or other markers indicative of their undifferentiated state, by means of different methods which are known in the art, such as immunocytometry, immunocytochemical analysis, RT-PCR, gene expression analysis in microarrays, proteomic studies or differential display analysis.
[0145] Stem cells can be induced to differentiate in vitro to produce dermal and epidermal cells according to any methods known in the art, such as those described in Oceguera-Yanez, F. et al, Front Cell Dev Biol 10: 1030339 (November 2022) and Kim, Y. et al, Stem Cell Res Ther 9:217 (2018). The differentiated cells may be identified by methods commonly used in the art, e.g., by immunocytochemistry, gene expression assays, cell functional assays or morphological observations.
[0146] The polymerisation reaction used to form the hydrogels herein is desirably conducted in a manner that avoids prolonged exposure of the cells to potentially cytotoxic conditions such as heat, light and / or chemical exposure. It is desirable to control the amount of heat, light and / or chemicals that the cells are exposed to as well as the duration of such exposure to maximise cell viability upon encapsulation in the hydrogel. While not wishing to be bound to any particular theory or reaction mechanism, one particularly desirable polymerisation process that provides for control of the polymerisation reaction during hydrogel formation can be characterised as free-radical water-dispersed photopolymerisation.
[0147] Free-radical water-dispersed hydrogel photopolymerisation comprises photo- initiation of an initiator using radiation that is compatible with the initiator chemistry (e.g., ultraviolet irradiation) in the presence of a polymerisable aqueous hydrogel precursor mix. The hydrogel precursor mix may contain macromonomeric units, additional crosslinking agents, and cells and / or biomolecules to be encapsulated in the hydrogel.
[0148] In some embodiments, the hydrogel is a photopolymerised hydrogel. Photopolymerisation may offer certain advantages over other methods of polymerisation, e.g., polymerisation is rapid, thus ensuring even distribution of magnetic particles and cells in the hydrogel, and minimising cellular damage (e.g., from heat production during polymerisation). Photopolymerisation may also produce covalently crosslinked networks that are more uniform and stable, and it may allow spatial and temporal control over the polymerisation process so that, for example, hydrogel precursors may be injected into a subject and photopolymerised in situ on demand. PEG macromonomeric units are capable of efficient photopolymerisation since their molecular structure is relatively free of components that would compete with crosslinking moieties by absorbing light.
[0149] Any wavelength of light may be used for photopolymerisation, although wavelengths in the ultraviolet (UV) and visible range are most common. Ultraviolet light with a wavelength between 300 and 400 nm may be used. Initiators may be used to activate one or more crosslinking moieties (e.g., a thiol group) for polymerisation. Initiator concentration can affect variables such as polymerisation time and the mechanical properties of the polymeric material. Useful photoinitiators are those which are water soluble, cause minimal cytotoxicity during polymerisation, and allow polymerisation within a short time frame, minutes at most and most preferably seconds. Non-limiting examples of photoinitiators for UV or visible-light initiation include eosin-Y, ethyl eosin, Irgacure 2959 and related derivatives of a -hydroxy ketones, lithium phenyl- 2,4,6-trimethylbenzoylphosphinate (LAP) and other phosphine derivatives, camphorquinone and its derivatives, and riboflavin. Other suitable photoinitiators are described in Tomal, W. and Ortyl, J. [Polymers 12(5): 1073 (2020)].
[0150] In some embodiments, the hydrogel is formed from an injectable liquid precursor. In general a liquid precursor for the hydrogel will comprise an aqueous mixture of PEG macromonomeric units, one or more functionalised cell adhesion motifs, functionalised magnetic particles, and dermal and epidermal cells. The precursor may further comprise an initiator for activating hydrogel polymerisation. An injectable liquid precursor may be of a viscosity that permits injection into a subject but retains the precursor at the site of injection until polymerisation is complete. Prior to injection, the liquid precursor is thoroughly mixed to reduce sedimentation and aggregation of the magnetic particles and cells. This may allow more effective crosslinking to give a uniform polymer network upon polymerisation. It may also give a more even distribution of cells and magnetic particles within the hydrogel.
[0151] The injectable and UV-crosslinkable nature of the hydrogel allows for easy delivery and precise filling of wound cavities, promoting effective healing even where the wound is irregularly shaped. Under UV irradiation, the magnetic liquid precursor solution can become solid hydrogel with the advantage of injectability. This also minimizes cell and particle aggregation and sedimentation.
[0152] The hydrogel may be formed with or without a mold. In some embodiments, the hydrogel is formed in a mold to give a specific shape to the hydrogel. In some embodiments, the hydrogel is formed in situ after the hydrogel precursor is introduced to a biological site, such as a tissue in a subject.
[0153] The magnetic PEG hydrogel undergoes deformation in the presence of a magnetic field, which in turn provides mechanical stimulation to the encapsulated cells, and induces changes to cell behaviour. The magnitude of the magnetic deformation and thus the extent of the mechano-stimulation provided by the hydrogel may be adjusted by varying the size of the magnetic particles, the concentration of the particles in the hydrogel and the strength of the magnetic field applied. In general, a higher concentration of larger particles will give a larger amplitude of deformation and thus greater mechanical stimulation to the cells. A lower concentration of particles may be coupled with a stronger magnet to achieve similar magneto-mechanical stimulation. Without wanting to be bound by theory, external magneto-mechanical stimulation can provide directional hydrogel deformation to enhance interstitial liquid flow within the hydrogel, which may in turn encourage cell migration and accelerate biomolecule release from the hydrogel.
[0154] In some embodiments, the one or more biological responses that the hydrogel stimulates is selected from the group consisting of cell migration, cell proliferation, cell production of extracellular matrix material, and cell secretion of biomolecules. Both the encapsulated dermal and epidermal cells may exhibit changes in one or more of these cell behaviours. However, the range of biological responses that may be stimulated is not to be taken to be limited to these behaviours, and the encapsulated cells may exhibit other responses that may also be beneficial to wound healing, e.g., increased intercellular contact, remodelling of the extracellular matrix, further differentiation to specific cellular sub-types.
[0155] In some embodiments, the one or more biological response is selected from the group consisting of increased cell migration out of the hydrogel, increased cell proliferation, increased production of type I collagen, and increased secretion of vascular endothelial growth factor (VEGF).
[0156] In some embodiments, magnetic deformation of the hydrogel induces migration of the encapsulated cells. The migration of the cells may be non-directional. The cells may migrate within the hydrogel, or into or out of the hydrogel. In this regard, the cell may migrate independently of the vector field provided by the magnetic flux. In one embodiment, magnetic deformation of the hydrogel induces migration of the encapsulated cells out of the hydrogel. For a hydrogel implanted at the site of a wound in a subject, cell migration may be towards the wound site.
[0157] In some embodiments, magnetic deformation of the hydrogel increases proliferation of the encapsulated cells.
[0158] In some embodiments, magnetic deformation of the hydrogel increases the production of extracellular matrix (ECM) material from the encapsulated cells. The ECM material may be a polymer, e.g., collagen. The ECM material may be laid down within and / or outside the hydrogel matrix. In one embodiment, magnetic deformation of the hydrogel increases production of collagen type I from encapsulated cells.
[0159] In some embodiments, magnetic deformation of the hydrogel increases the secretion of biomolecules from the encapsulated cells. Non-limiting examples of secreted biomolecules include cytokines, chemokines and growth factors, e.g., fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), transforming growth factor [3 (TGFP), interleukin 1 (IL-1). The secreted biomolecule may effect changes at the wound site that promote wound healing. Alternatively or in addition, the secreted biomolecule may produce a biological effect in one or both of the encapsulated cells. In one embodiment magnetic deformation of the hydrogel increases the secretion of VEGF from encapsulated cells.
[0160] In some embodiments, the hydrogel further comprises one or more encapsulated compounds selected from the group consisting of a cytokine, a hormone, a growth factor, an anti-inflammatory compound and an antimicrobial compound. The hydrogel may also contain one or more of an enzyme, a signalling molecule, a serum protein, an extracellular matrix protein, an antibody, an antipyretic, an analgesic, a dermatological drug, a vitamin and a mineral. The one or more encapsulated compounds may promote wound healing and / or provide a pharmacological effect in a subject. Cytokines, hormones and growth factors include proteins from natural sources and from recombinant cell culture, and biologically active equivalents of the native sequence proteins. Non- limiting examples of these compounds include insulin, proinsulin, endothelin, leptin, fibroblast growth factor (FGF) such as FGF1, FGF2 and FGF7, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet- derived growth factor (PDGF), nerve growth factor (NGF) such as NGF-0, transforming growth factor (TGF) such as TGF-01 and TGF-02, insulin-like growth factor-I and -II, and interleukins (ILs) such as IL-1 and IL-4.
[0161] Anti-inflammatory compounds include corticosteroids (e.g., hydrocortisone and its derivatives, dexamethasone and its derivatives, and prednisone and its derivatives), diclofenac and other acetic acid derivatives (e.g., indomethacin and bromfenac), salicylic acid, aspirin (acetylsalicyclic acid), acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, mniroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid.
[0162] Antimicrobial compounds include antibiotics, antivirals, antibacterials and antifungals. Non-limiting examples of antimicrobial compounds include salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid (e.g., 5-octanoyl salicylic acid), benzoyl peroxide, triclosan, triclocarbon, ionic silver, eucalyptol, menthol, thymol, methylsalicylate, azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, flucytosine, chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactames, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin, polymyxin B, and clindamycin.
[0163] In one embodiment, the hydrogel further comprises encapsulated insulin to modulate blood glucose levels in the subject.
[0164] In some embodiments, the hydrogel regulates release of the one or more encapsulated compounds when deformed in the presence of a magnetic field. Without wanting to be bound by theory, magnetic deformation of the hydrogel may generate interstitial fluid flow within the hydrogel, which increases the diffusion and exchange rate of loaded compounds.
[0165] In some embodiments, the magnetically responsive hydrogel further comprises an adhesive dressing which borders the magnetically responsive hydrogel. The adhesive dressing may keep the hydrogel in place at the site of a wound in a subject.
[0166] Disclosed herein is a kit for forming a magnetically responsive hydrogel, comprising : a) polyethylene glycol diacrylate (PEGDA) macromonomeric units; b) magnetic particles each functionalised with thiol moieties; c) cell adhesion motif precursors each comprising an acrylate moiety; and d) dermal and epidermal cells; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm.
[0167] In some embodiments, the kit further comprises a photoinitiator.
[0168] The components of the kit, such as the PEGDA macromonomeric units, cell adhesion motif precursors and / or photoinitiator, may be provided in liquid form or in solid form. Solid forms include but are not limited to powders, films and freeze-dried solids. The solids may be reconstituted in a suitable solvent or buffer, such as a cell-compatible aqueous buffer, prior to use in hydrogel formation.
[0169] Liquids and reconstituted solids in the kit may be mixed in predetermined ratios to form a liquid precursor for a magnetically responsive hydrogel.
[0170] Disclosed herein is a liquid precursor of a magnetically responsive hydrogel, comprising: a) polyethylene glycol diacrylate (PEGDA) macromonomeric units; b) magnetic particles each functionalised with thiol moieties; c) cell adhesion motif precursors each comprising an acrylate moiety; and d) dermal and epidermal cells; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm.
[0171] Preferably, the liquid precursor comprises a solvent that is biocompatible with the cells, such as an aqueous buffer or a saline solution.
[0172] In some embodiments, the liquid precursor further comprises a photoinitiator.
[0173] In some embodiments, the liquid precursor comprises about 2% w / w to about 15% w / w of PEG macromonomeric residues relative to the liquid precursor, wherein the component percentage refers to the dry weight of the PEG macromonomeric residues relative to the total weight of the liquid precursor. The liquid precursor may comprise about 2% w / w to about 5% w / w, about 5% w / w to about 7.5% w / w, about 7.5% w / w to about 10% w / w, about 10% w / w to about 12.5% w / w, or about 12.5% w / w to about 15% w / w PEG macromonomeric units. In some embodiments the liquid precursor comprises about 5% w / w to about 10% w / w of PEG macromonomeric units. In one embodiment the liquid precursor comprises about 5% w / w PEG macromonomeric units relative to the hydrogel. In some embodiments, the concentration of magnetic particles in the liquid precursor is about 0.5% w / w to about 2% w / w relative to the liquid precursor, wherein the component percentage refers to the dry weight of magnetic particles used relative to the total weight of the liquid precursor. The concentration of the magnetic particles may be about 0.5% w / w, about 0.6% w / w, about 0.7% w / w, about 0.8% w / w, about 0.9% w / w, about 1% w / w, about 1.1% w / w, about 1.2% w / w, about 1.3% w / w, about 1.4% w / w, about 1.5% w / w, about 1.6% w / w, about 1.7% w / w, about 1.8% w / w, about 1.9% w / w, or about 2% w / w relative to the liquid precursor. The concentration of the magnetic particles may be at least 0.5% w / w, at least 0.6% w / w, at least 0.7% w / w, at least 0.8% w / w, at least 0.9% w / w, or at least 1% w / w relative to the liquid precursor. In one embodiment the concentration of magnetic particles is about 0.5% w / w relative to the liquid precursor.
[0174] In some embodiments, the cell adhesion motif is present at a concentration of about 0.2% w / w to about 0.6% w / w relative to the liquid precursor, wherein the component percentage refers to the dry weight of the cell adhesion motif precursor relative to the total weight of the liquid precursor. The cell adhesion motif may be present at a concentration of about 0.2% w / w, about 0.22% w / w, about 0.24% w / w, about 0.26% w / w, about 0.28% w / w, about 0.3% w / w, about 0.32% w / w, about 0.34% w / w, about 0.36% w / w, about 0.38% w / w, about 0.4% w / w about 0.42% w / w, about 0.44% w / w, about 0.46% w / w, about 0.48% w / w, about 0.5% w / w, about 0.52% w / w, about 0.54% w / w, about 0.56% w / w, about 0.58% w / w, or about 0.6% w / w relative to the liquid precursor. In one embodiment the cell adhesion motif is present at a concentration of about 0.4% w / w relative to the liquid precursor.
[0175] In some embodiments, the liquid precursor comprises about 105to about 107dermal and epidermal cells. In one embodiment the hydrogel comprises about 106dermal and epidermal cells.
[0176] In some embodiments, the ratio of dermal cells to epidermal cells in the liquid precursor is about 1 : 10 to about 10: 1. In one embodiment the ratio of dermal cells to epidermal cells is about 1 : 1. The liquid precursor may be polymerised with or without a mold to form the hydrogel. In some embodiments, the liquid precursor is introduced to a biological site, such as a tissue in a subject, and polymerised in situ.
[0177] Disclosed herein is a system for use in wound healing, comprising: a) a magnetically responsive hydrogel as disclosed herein; and b) magnetic means for mechanically deforming the hydrogel.
[0178] The term "magnetic means" as used herein refers to any means by which a magnetic field may be generated or maintained during the normal operation of a system, device or method. In some embodiments, the magnetic means comprises a magnet, e.g., a permanent magnet. The magnet may comprise one or more of the metals iron, cobalt, nickel, aluminium, copper, manganese, zinc, titanium, samarium, neodymium, yttrium and dysprosium, or an oxide or alloy thereof. Permanent magnets are available commercially in a variety of shapes and strengths. The magnet may be provided with a means to adjust the effective magnetic field strength at the hydrogel when in use with the hydrogel. One such means may be, for example, an adjustable platform or a similar displacement mechanism to increase or reduce the distance of the magnet to the hydrogel.
[0179] In some embodiments, the magnetic means comprises an electromagnet, which generates a magnetic field through the application of an electric current. The strength of the magnetic field generated by an electromagnet is more easily controllable by adjusting the electric current flowing through the electromagnet.
[0180] The magnetic means may be chosen to provide a sufficient maximum magnetic flux density to deform a hydrogel that is implanted in a subject when the magnetic means is applied to the subject externally.
[0181] In some embodiments the magnetic means is capable of generating a magnetic field with a maximum magnetic flux density of about 0. 1 T to about 1 T. In some embodiments the magnetic means is capable of generating a magnetic field with a maximum magnetic flux density of at least 0.01 T, at least 0.05 T, at least 0.1 T, at least 0.2 T, at least 0.3 T, at least 0.4 T, at least 0.5 T, at least 0.6 T, at least 0.7 T, at least 0.8 T, at least 0.9 T, or at least 1 T. In some embodiments the magnetic means is capable of generating a magnetic field with a maximum magnetic flux density of about 0.1 T, about 0.2 T, about 0.3 T, about 0.4 T, about 0.5 T, about 0.6 T, about 0.7 T, about 0.8 T, about 0.9 T, or about 1 T.
[0182] In some embodiments, the magnetic means is capable of generating a periodic magnetic field. The periodic magnetic field may be a time-varying magnetic field, such as a magnetic field with a maximum magnetic flux density that varies with time. The periodic magnetic field may have a constant frequency. Without wanting to be bound by theory, a periodic magnetic field allows dynamic mechanical stimulation of encapsulated cells so as to induce one or more biological responses from the cells.
[0183] In some embodiments, the magnetic means is capable of generating a periodic magnetic field with a frequency of about 0.1 Hz. The use of a periodic magnetic field with a low frequency reduces the amount of heat generated during cyclic hydrogel deformation, thus reducing potential injury to the encapsulated cells and / or to the tissue where the hydrogel is applied.
[0184] Disclosed herein is a method for stimulating a biological response in a cell, the method comprising encapsulating the cell in a magnetically responsive hydrogel as disclosed herein, and applying a magnetic field to deform the hydrogel to stimulate one or more biological responses from the encapsulated cells.
[0185] In some embodiments, the cell is a dermal or an epidermal cell.
[0186] In some embodiments, the applied magnetic field has a maximum magnetic flux density of about 0.1 T to about 1 T. In some embodiments the applied magnetic field has a magnetic flux density of at least 0.01 T, at least 0.05 T, at least 0.1 T, at least 0.2 T, at least 0.3 T, at least 0.4 T, at least 0.5 T, at least 0.6 T, at least 0.7 T, at least 0.8 T, at least 0.9 T, or at least 1 T. In some embodiments the applied magnetic field has a magnetic flux density of about 0.1 T, about 0.2 T, about 0.3 T, about 0.4 T, about 0.5 T, about 0.6 T, about 0.7 T, about 0.8 T, about 0.9 T, or about 1 T.
[0187] In some embodiments, the applied magnetic field is a periodic magnetic field, for example, a magnetic field with a maximum magnetic flux density that varies with time. The periodic magnetic field may have a constant frequency, such as a frequency of about 0. 1 Hz.
[0188] The magnetic field may be applied for stretches of several minutes or several hours at a time to provide sufficient mechanical stimulation to induce changes in cell behaviour.
[0189] The biological effect may be a change in cell migration, a change in cell proliferation, a change in cell production of extracellular matrix material, and / or a change in cell secretion of biomolecules.
[0190] The extent of the biological effect may be regulated by varying the duration and strength of the magnetic field applied. The biological effect may also be temporally regulated by varying the frequency of application of the magnetic field, e.g., encapsulated cells may be induced to secrete a biomolecule in a cyclical manner through the cyclical application of a magnetic field, or through cyclical changes to the strength of the magnetic field applied. Without wanting to be bound by theory, the ability to control cell behaviour in this way may prevent cell exhaustion or senescence when the cells are used clinically to generate a biological effect.
[0191] Disclosed herein is a method of treating a wound in a subject in need thereof, the method comprising contacting a magnetically responsive hydrogel as disclosed herein with the wound in the subject, and applying a magnetic field to deform the hydrogel to stimulate one or more biological responses from the encapsulated cells.
[0192] In some embodiments, the applied magnetic field has a maximum magnetic flux density of about 0.1 T to about 1 T. In some embodiments the applied magnetic field has a magnetic flux density of at least 0.01 T, at least 0.05 T, at least 0.1 T, at least 0.2 T, at least 0.3 T, at least 0.4 T, at least 0.5 T, at least 0.6 T, at least 0.7 T, at least 0.8 T, at least 0.9 T, or at least 1 T. In some embodiments the applied magnetic field has a magnetic flux density of about 0.1 T, about 0.2 T, about 0.3 T, about 0.4 T, about 0.5 T, about 0.6 T, about 0.7 T, about 0.8 T, about 0.9 T, or about 1 T.
[0193] In some embodiments, the applied magnetic field is a periodic magnetic field, for example, a magnetic field with a maximum magnetic flux density that varies with time. The periodic magnetic field may have a constant frequency. In some embodiments, the applied magnetic field is has a constant frequency of about 0.1 Hz.
[0194] The magnetic field may be applied for stretches of several minutes or several hours at a time to provide sufficient mechanical stimulation to induce changes in cell behaviour. In some embodiments, the magnetic field is applied for at least about 1 hour a day, such as about 1 hour daily, about 2 hours daily, about 3 hours daily, about 4 hours daily, about 5 hours daily, or about 6 hours daily.
[0195] In some embodiments, the hydrogel is contacted with the wound for at least about 24 hours. For example, the hydrogel may be contacted with the wound for at least about 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days. The hydrogel may be contacted with the wound for about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, or longer. In some embodiments, the hydrogel is contacted with the wound for at least 3 days.
[0196] A subject herein may be any single subject for which wound healing is desired, including humans, cattle, horses, pigs, goats, sheep, dogs, cats, guinea pigs, rabbits, rats, mice, chickens, and so on. Also intended to be included as a subject are any subjects involved in clinical research trials not showing any clinical sign of disease, or subjects used as controls.
[0197] The hydrogel may be surgically implanted at the wound site or applied as a dressing to the wound in the subject. Alternatively, a hydrogel precursor mix may be injected at the wound site and polymerised in situ to form the magnetically responsive hydrogel.
[0198] In some embodiments, the subject is suffering from diabetes mellitus, e.g., Type I or Type II diabetes. In some embodiments, the wound is a skin ulcer. The wound may also be other types of wounds that require clinical intervention, non-limiting examples of which include a chronic wound, an open wound, a traumatic wound, an ulcerating wound, an infected wound, a burn, a penetrating wound, a bite (e.g., an insect or animal bite), a malignant wound (e.g., a wound caused by an invading cancer), and a wound or post-operative site that has developed complications.
[0199] The encapsulated dermal and epidermal cells may be autologous, syngeneic or allogeneic with respect to the subject. The encapsulated dermal and epidermal cells may be derived from stem cells which are autologous, syngeneic, allogenic or xenogeneic with respect to the subject.
[0200] Disclosed herein is a magnetically responsive hydrogel as defined herein for use in treating a wound in a subject in need thereof, wherein the hydrogel is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
[0201] Disclosed herein is the use of a magnetically responsive hydrogel as defined herein in the manufacture of a medicament for treating a wound in a subject in need thereof, wherein the hydrogel is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
[0202] Examples
[0203] Methods
[0204] Polyethylene Glycol Diacrylate (PEGDA) synthesis and characterization Briefly, acryloyl chloride was added in a dropwise fashion, into a mixture of distilled dichloromethane (DCM), poly(ethylene glycol), and triethylamine (TEA). The reaction mixture was continuously stirred for 24 h in darkness and nitrogen atmosphere, to avoid light exposure and hydrolysis. Following that, the mixture was washed with potassium bicarbonate, dried over anhydrous sodium sulfate, and precipitated with cold diethyl ether. The mixture was then placed in dialysis tubing (22 mm with different intercepted molecular weight, all purchased from Thermo Fisher) and dialyzed in deionized water for 5 days. The solution in the dialysis bag was first filtered through a 70-pm strainer (#542070, Greiner Bio-one) and lyophilized for 3 days (Freeze Dryer, LyoLab 105, Qingdao Antech Scientific CO., LTD) to yield PEGDA powder. All reaction reagents were obtained from Sigma-Aldrich.
[0205] -H-NMR was used for analyzing the chemical composition of products. It was recorded using 400 MHz Spectrometer (AVIII400, Bruker) at 25°C in deuterium oxide (DLM-4-100, Cambridge Isotope Laboratories, Inc.). Degree of acrylation (i.e., PEG end group conversion rate) could be calculated through the signals ratio of proton on the unsaturated bonds by the equation : where f Acrylates (at+ cz2) was the integrated ratio of1H proton on unsaturated bonds (peak a), and J PEG backbone^) was the integrated ratio of1H proton on PEG backbone. Due to the instability of grafted unsaturated bond, its maintenance was also calculated by: where f motified group (h) was the integrated ratio of1H proton on grafted end group.
[0206] Preparation of magnetic hydrogel
[0207] Reaction-generated PEGDA powder, RGD peptide Acryloyl powder, and thiol- coated magnetic particle (TMP) were mixed in Dulbecco's phosphate-buffered saline solution (PBS; D8537, Sigma-Aldrich) at a pre-determined mass proportion. Following that, Lithium phenyl-2,4,6-trimethylbenzoylphosphinate powder (LAP photo-initiator; VLLP0001, Cellink) was added to the solution and was exposed to UV lamp (EFL-LS-1601-405, EngineeringForLife) for 1 min. The UV lamp was set at a wavelength of 405 nm and an intensity of 25 mW / cm2, which is suitable for cell and animal works. To avoid particle agglomeration and sedimentation in the hydrogel, hydrogel precursor solution underwent ultrasonic dispersion before UV crosslinking. Hydrogel material characterization
[0208] The hydrogel photo-gelation was characterised by rheometer (DHR-2, TA instrument). Accompanied by a 20 mm diameter parallel geometry, the storage modulus (G1) and loss modulus (G") of samples before or after UV exposure were measured, as functions of test time. For biomedical applications, it is critical to test its stability under physiological conditions. The hydrogel constructs were immersed in physiological (pH 7.4) PBS solution, in 24 well plate which placed in shaking incubator (ZWY-100H, LABWIT) at 37°C. To measure the in vitro degradability, samples were lyophilized and weighed at desired time points. The mass retention of hydrogels (W) represented the condition of degradation and was calculated by the following equation: where Wo was the weight of the initial lyophilized hydrogel, and Wt was the weight of the lyophilized hydrogel after culturing for a desired period.
[0209] The in vitro swelling ratio was calculated by the equation: where Mo was the weight of the initial hydrogel, and Mt was the weight of the hydrogel after culturing for a desired period.
[0210] Considering abnormal pH condition at wound sites, for example the pH at diabetic wound ranges from 5 to 9, it is valuable to test the gel stability in this pathological conditions. To improve cell growth and spreading phenotype in the hydrogel, RGD motif was introduced into the hydrogel system. The RGD grafting condition was confirmed by fluorescent intensity which was modified from reference.
[0211] The mechanical features of hydrogel were profiled by compression testing machine (EZ-SX, SHIMADZU). The tested hydrogels (different mass concentrations or UV exposure lengths) were cut into cylinder pieces (9.0 mm in diameter and 5.0 mm in height) and compressed at a strain of 20% by 15 mm diameter parallel geometry. The Young's modulus was obtained through the equation : where F was the applied force, L was the gel initial height, AL was the change of height, and A was the gel surface area. The elasticity of hydrogel was tested by conducting 100 loading-unloading cycles (30 s 50% strain compression loading, 30 s holding, 30 s unloading to initial state, 30 s holding).
[0212] The microstructure of hydrogel was observed via scanning electron microscope (SEM; JSM-6701F FEG, JEOL), and the morphology of TMP was investigated by transmission electron microscope (TEM; JEM-1400Flash, JEOL). The pore size of hydrogel network was analyzed by ImageJ. Plus, Zetasizer (ZEN360, MALVERN Instruments Limited) was used to measure the hydrodynamic diameter of TMP. The magnetic properties of the PEGDA-RGD-TMP hydrogel and pure TMP powder were characterised by superconducting quantum interference device (SQUID) magnetometer (MPMS3, Quantum Design Inc.) with a maximum applied magnetic field of 10 kOe at room temperature.
[0213] Preparation of cell-hydrogel composite
[0214] Prior to cell experiments, warm hydrogel precursor solution was sterile-filtered using 0.22 pm polyethersulfone (PES) syringe filters (16532, Sartorius). The cells were washed by PBS and harvested by trypsinization (0.25% Trypsin- EDTA, 25200072, Gibco), then completely re-dispersed in hydrogel precursor solution at desired cell density for use. Following which, the cell / gel mixture was added into well plate or petri dish, and immediately photo-crosslinked by UV lamp to avoid cell and TMP sedimentation. Before magneto-stimulation, 2-day static pre-culture was taken for cell adaption and spreading in the hydrogel, which has been shown as a pre-condition for external mechanical stimulation.
[0215] Characterization of 3D cell-loaded hydrogel
[0216] The 3D distribution of encapsulated cells (DAPI-labelled) and loaded TMPs (fluorescent-labelled) were characterised by confocal microscope (LSM710, Zeiss) and the data was analyzed by ImageJ and Imaris (version 9.7). The 2D distribution of TMP in gel was imaged using fluorescent microscope (TI2-N-ND- E, Nikon). To determine the biocompatibility of hydrogel and feasibility of external mechano-stimulation, Cell Counting Kit 8 (CCK8; ab228554, Abeam) and LIVE / DEAD™ Cell Imaging Kit (R37601, Thermo Fisher) were used to measure cell proliferation rate and material cytotoxicity. Cells were cultured in hydrogel at different conditions including pure PEGDA-RGD hydrogel, pure PEGDA-RGD-TMP hydrogel, and PEGDA-RGD-TMP hydrogel with magnetic stimulation, which recorded or imaged at desired time points (day 0, 1, 4, 7, and 14) by spectrophotometer (Multiskan Go Type 1510, Thermo Fisher) and fluorescent microscope (TI2-N-ND-E, Nikon). The change in numbers of encapsulated fibroblasts and keratinocytes were measured using DNA quantification assay through Quant-iT™ PicoGreen™ dsDNA Assay Kits (P11496, Thermo Fisher).
[0217] Device and calculation of external magneto-induced dynamic mechanical stimulation
[0218] To achieve dynamic magneto-mechanical stimulation on the cell-loaded PEGDA- RGD-TMP hydrogel, a neodymium permanent magnet (NdFeB Block Magnet) was installed on a rotary machine (with periodic displacement at 0.1 Hz), with reference to our previous work [Tay et al, Adv Mater 30: 1800927 (2018)]. The hydrogel constructs were attached at the bottom of well-plate or petri dish, and the cyclic magnetic forces would transduce into mechanical perturbations on loaded cells. Since the magnetic field strength (or magnetic flux density) of permanent magnet is inversely proportional to the distance, the force amplitude of each TMP (FTMP) could be calculated by: where V was the average volume of TMP, AXpwas magnetic susceptibility, uo was magnetic permeability, (B - V) was experimentally determined equation between magnetic field and distance to permanent magnet, and B was applied magnetic field. In this experiment, the stimulation duration was 0-3 days, and the range of applied force could be adjusted by distance between hydrogel construct and rotated magnet (20-80 mm).
[0219] Multiphysics modeling for hydrogel deformation and drug release
[0220] The present multiphysics model is developed to characterize the magneto- responsive hydrogel system, referred to our previous work with modification [Shou et al, Bioact Mater 24:387-400 (2023)]. The model considers the magnetization, deformation of the hydrogel, as well as the diffusions of the solvent and drug molecules (fig. 32). The computational domain consists of hydrogel and its surrounding.
[0221] {1} Governing equations
[0222] In magnetostatics, the Maxwell's equations are employed to describe the magnetic field H and induction B, namely where 7 x (•) and 7 • (•) are the material curl and divergence operators respectively in reference configuration with respect to the Lagrangian coordinate X. The material magnetic field H and induction B are connected by where p0is the magnetic permeability at vacuum, M is the material magnetization vector, J = det(F) is the determinant and J > 0 , F is the deformation gradient, and C = FTF is the right Cauchy-Green tensor. From Equation (1), it is known that the magnetic field H can be rewritten as the negative gradient of the magnetic scalar potential namely
[0223] At the hydrogel-surrounding interface, the magnetic variables are required to satisfy the following jump conditions where N is the unit normal vector, and the double bracket [[■]] denotes a quantity jump across the surface from the inside to outside of the material.
[0224] For characterization of the fluid transport, the mass balance is utilized by where Cf(X, t) is the concentration of fluid including solvent and drug molecules, J, is the flux density of the fluid flowing into the hydrogel across the interface, and Rf is the number of fluid generation per unit reference volume per unit time. To describe the large deformation of the hydrogel, the balance of momentum is used where p0is the nominal mass density of the polymer matrix, P is the nominal stress, Vhis the deformation velocity, and fbis the external force density.
[0225] {2} Constitutive relations
[0226] On the basis of thermodynamics, it is stated that the temporal increase in the free energy of the hydrogel system is not larger than the external power and the free energy due to fluid diffusion and hydrogel magnetization, namely where w is the free energy density and ptis the chemical potential.
[0227] According to Equations (5) and (6), and applying the divergence theorem, the local form of the free energy imbalance (7) is achieved as
[0228] If the deformation gradient F , magnetic induction B, and fluid concentration cfare used as the independent variables, i.e., w = w(F,B,cr), we obtain
[0229] Due to the arbitrariness of the variables, the coefficient vanishes in any bracket. In addition, to guarantee the inequality (8) hold, the fluid is written as the negative gradient of chemical potential where the positive-definite tensor f r / (B) (here Dfdenotes the diffusion coefficient, and kgT is the temperature in the unit of energy). Therefore, the constitutive relations are obtained as
[0230] Instead of magnetic induction B, if the intensity H is utilized as the independent variable, an augmented free energy density is needed and achieved by the partial Legendre transformation hence the relation (11) is recast as
[0231] {3} Free energy density
[0232] For a description of the response of the hydrogel, a specific free energy density Ω is required. In this study, the free energy density of the present hydrogel system is composed of three parts, i.e., stretching of the polymeric network ^eia i mixing of the polymer and fluid molecules Qmix, as well as the magnetization of the hydrogel Qmag. If the molecular incompressibility condition is considered, i.e., 1 + vscs= det(F), we have the specific free energy density below where G represents the hydrogel shear modulus, is the volume per fluid species, is the Flory-Huggins parameter that describes the polymer-fluid interaction, p.mis the magnetic permeability of the hydrogel and related to the relative permeability pmrthrough and n is the Lagrange multiplier (20). According to the constitutive relation (13) and the free energy function
[0233] 14)
[0234] (15), the nominal stress P , the magnetic induction B , and the chemical potential are respectively given below
[0235] For simplicity, by Equations (3) and (17), the governing equation (1) for the magnetic intensity and induction are rewritten as a function of magnetic potential V'
[0236] {4} Boundary and initial conditions
[0237] For solving the governing equations with their relevant constitutive relations, it is vital to determine the initial and boundary conditions and they are listed as follows.
[0238] At the edge of the surrounding fluid, when the magnetic field applied is nonuniform generated by a magnet, the boundary condition for the magnetic potential <p is achieved from the experimental measurement based on the reconstruction method (17). At the interface between the hydrogel and the surrounding, the following boundary conditions are employed: where p is the hydrogel boundary, / if* denotes the chemical potential of the surrounding fluid. It is noted that and = 0 if the hydrogel is immersed in solvent surrounding. Tais the mechanical traction and Tm= Pm- N is the magnetic traction, here the Maxwell stress Pmis given by Regarding the magnetic hydrogel at the initial time, we have the initial conditions below:
[0239] Ay = H / o, P = 0 (22) where the initial chemical potential nf0is obtained by Equation (18) by setting the stress P = 0 in Equations (16).
[0240] Currently, the magnetic-chemo-mechanical model has been theoretically formulated for the magnetic hydrogel. It comprises the magnetostatic equation (19), the mass conservation equation (5), and the mechanical balance equation
[0241] (6). Moreover, the specific free energy density is given by Equation 14)
[0242] (15) for hydrogel system, and the constitutive relations are included via Equations (10), (16), (17), and (18). The coupled partial differential equations are solved by finite element method through the COMSOL package.
[0243] Cell isolation and culture
[0244] For in vitro experiments, both primary and immortalized human dermal fibroblast (FB) and human epidermal keratinocyte (KC) were used cell sources, for single or co-cultured in the magnetic hydrogel system. Immortalized FB and KC cells were cultured in high glucose Dulbecco's modified eagle medium (HG- DMEM; 11965092, Gibco) supplemented with 10% Fetal Bovine Serum (FBS; 10270106, Gibco) and 1% Penicillin-Streptomycin (P / S; Antibiotic-Antimycotic, 15240062, Gibco), at 37°C and 5% CO2 cell incubator and sub-cultured every 3 days. Early passage human dermal fibroblasts and epidermal keratinocytes were obtained from the Asian Skin Biobank (ASB) at the Skin Research Institute of Singapore (SRIS). They were derived from abdomen skin of a 44-year-old Caucasian female. The use of human cells for research purposes has been approved by the ethics committee reference: NUS-IRB-2022-276. Primary human fibroblast was cultured in HG-DMEM supplemented with 10% FBS and 1% P / S, and primary human keratinocyte was cultured in complete FAD medium which contained a mixture of DMEM and Ham's F12 at a 3: 1 ratio, 10% FBS, 1% P / S, epidermal growth factor, insulin, 3,3',5-triiodo-L-thyronine, hydrocortisone, adenine, and cholera toxin. To better expand the primary human keratinocyte, y irradiation-treated 3T3-J2 cell line was utilized as feeder cells. The cell culture was supported and monitored by Cell Analyzer (Countstar Mira BF, Countstar Inc.). For in vivo experiments, mouse dermal fibroblast and epidermal keratinocyte were separately isolated from mice back skin and cultured, based on the methods and video protocols from JoVE.com. All cell culture dishes / plates were obtained from NEST Biotechnology Co. Ltd.
[0245] Quantitation of secreted VEGF concentration
[0246] After collecting supernatant from conditioned medium from each culture conditions, the supernatant was filtered through 0.70 mm strainers (#542070, Greiner Bio-one). The final concentration of VEGF in the conditioned medium was measured using commercially available VEGF ELISA kits (#F03060, Shanghai Xitang Biotech) and quantified using spectrophotometer (Multiskan Go Type 1510, Thermo Fisher).
[0247] In vitro HUVEC assays
[0248] Primary human umbilical vein endothelial cells (HUVECs) were cultured in endothelial cell media kits from PromoCell, and cells from passages 5 to 7 were used for in vitro HUVEC assays. Each conditioned medium was collected from human fibroblast / keratinocyte-laden hydrogel and mixed with VEGF-free HUVEC culture medium at an optimized mixing ratio of 3:7 and used for in vitro HUVEC assay. Based on the previous study, HUVECs were unable to grow in pure conditioned mediums and a minimal amount (70%) of HUVEC culture medium was needed to keep HUVECs viable. Human VEGF-added (P5563, Beyotime) cell culture medium was included as a positive control in the experiment.
[0249] The effect of mechano-stimulated fibroblast / keratinocyte conditioned medium on chemotactic migration of HUVECs was determined by p-Slide Chemotaxis (#80306, ibidi), based on manufacturer's protocol. Briefly, cell suspension was added into each chip center chamber. After 6 h, seeded cells were attached at the chip chamber surface, VEGF-free culture medium was then introduced in the left (or lower) chamber, while the right (or upper) chamber was infused with the collected conditioned medium mixtures. Following that, the migratory behaviors of HUVECs were monitored by microsystem (DMIL LED Fluo, Leica). For each group, the migratory route was tracked by FastTrack Al Image Analysis (ibidi) and the values were obtained by manual tracking using the Image] Manual Tracking Plugin.
[0250] The effect of the various conditioned media on angiogenesis of endothelial cells was assessed by a fibrin gel bead sprouting assay, performed with modifications. Briefly, Cytodex 3 microcarrier beads (c3275, Sigma-Aldrich) were coated with HUVECs using a density of 400 cells / bead in endothelial cell growth medium. The cell-bead suspension was agitated and allowed to adhere overnight. Coated beads were subsequently suspended in fibrinogen solution (F-8630, Sigma-Aldrich) at a concentration of 500 beads / mL and mixed with 0.625 Units / mL thrombin directly. Gels were left for 5 min at room temperature, then incubated at 37°C to generate a clot. Solidified gels were then topped up with an equal volume of control or conditioned medium. Subsequently, the cells were incubated overnight at 37°C, 5% CO2 and observed for sprout formation after 6 using a phase contrast microscope (CKX53, Olympus).
[0251] In vitro HUVEC tubular network formation assay was performed using the p- Slide Angiogenesis (#81506, ibidi), based on manufacturer's protocol. Briefly, each well was first coated with gel matrix and seeded with a final cell number of 10000 cells, supplied with VEGF-free culture medium or each collected conditioned medium mixture. Samples were then incubated for 1 day to allow formation of capillary-like tubes and subsequently imaged using the fluorescent microscope (TI2-N-ND-E, Nikon) under brightfield and fluorescent laser (HUVECs were labelled by blue DAPI and green DiO (D4007, UElandy)). Brightfield images were analyzed with the FastTrack Al Image Analysis (ibidi). The number of loops and branches as well as total tube length were computed to quantify the extent of tube formation.
[0252] In vitro cell migration assay
[0253] To investigate the effect of external magneto-mechanical stimulation on cell migration out from hydrogel, an in vitro cell migration assay was conducted. Briefly, cell-loaded hydrogel precursor solution was injected and in situ gelled on the surface of cell culture dish (080122EQ01, NEST Biotechnology Co. Ltd.). Following which, the cell-loaded hydrogels were treated by different stimulation conditions, and the migrated cells from gel to dish surface were imaged with by microsystem (DMIL LED Fluo, Leica) at 36 h post-treatment. The cell types were differentiated by morphology directly and number of migrated cells was counted by Image!
[0254] Hemolysis Test
[0255] The hemolysis ratio of PEGDA-RGD-MP hydrogel was assessed by hemolysis test, performed with modifications. The blood was collected from BALB / c mice. Briefly, the sterilized samples were placed in 3 mL normal saline containing 0.06 mL erythrocyte stock dispersion, and cultured at 37°C for 1 h. After centrifuging the mixed solution, the absorbance values of the supernatant of each mixture were determined at 545 nm by microreader. Pure deionized water and normal saline with erythrocyte stock dispersion were set as positive and negative controls, respectively. The hemolysis ratio (%HR) was obtained by the following equation: where DS, DNC, and DPC are the absorbance values of the samples, the positive control, and the negative control, respectively.
[0256] In vitro insulin release analysis
[0257] Human insulin was mixed in the PEGDA-RGD-TMP hydrogel precursor solution at a concentration of 5 lU / mL, then injected and in situ gelled in the well plate. The insulin-containing magnetic hydrogels were immersed into phosphate- buffered saline (PBS) solution and incubated in an incubator shaker at 37°C. The hydrogel was treated with MDMS at desired time points. All culture solution in each well which contains released insulin was collected, filtered and stored in a fridge before measurement with an ultra-sensitive insulin ELISA kit (#63010, Shanghai Xitang Biotech) and spectrophotometer (Multiskan Go Type 1510, Thermo Fisher).
[0258] Diabetic animal skin defect model
[0259] All BALB / c mice (male, ~8 weeks, 18-20 g) were purchased from the Laboratory Animal Center of Sun Yat-sen University, and animal studies were carried out with the protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the Sun Yat-sen University (2022003331). A full-thickness excisional skin defect model was adopted based on previous protocol with modifications. Briefly, mice were injected with streptozotocin (STZ; 50 mg / kg, i.p.) to induce Type 1 diabetes model according to previous reports. Blood glucose was measured 1 week later, and mice with a blood glucose level above 16.7 mM for over 7 days were considered diabetic. Following that, after anesthetization and depilation, two full-thickness round skins were excised from the back of each mouse. To prevent local skin contraction, a splinting ring was tightly adhered to the skin around the wound, followed by covering Tegaderm transparent dressing (1624W, 3M). The animals were monitored daily.
[0260] In vivo diabetic wound healing evaluation
[0261] To investigate the MDMS-based strategy for diabetic wound healing, mice were randomly assigned into six groups (10 mice per group), which were treated with pure PEGDA-RGD-TMP hydrogel with '3 Day / 20 mm' MDMS, cell-loaded hydrogel without MDMS, cell-loaded hydrogel with '1 Day / 20 mm' MDMS, cell- loaded hydrogel with '3 Day / 80 mm' MDMS, cell-loaded hydrogel with '3 Day / 20 mm' MDMS, and control groups, and the MDMS was conducted 2 h / day. The hydrogel constructs were positioned on the wound site and covered with dressing to fix the hydrogel in place. The hydrogel / Tegaderm dressing was replaced daily. To study the wound-healing process, wounds were observed and captured by a digital camera on day 0, 3, 5, 7, 10, and 14. Wound areas were digitally measured relative to inner area of splinting rings using Image!, to calculate wound healing rate. Due to the remarkable therapeutic effects, some wound samples were completely healed on day 14.
[0262] Single-cell RNA sequencing analysis
[0263] Single-cell count matrices of nondiabetic (n = 4 individuals) and diabetic (n = 7) human forearm skin biopsies were downloaded from Gene Expression Omnibus (GEO) and processed with Seurat (Accession number: GSE165816) (75, 76). Cells with < 500 Unique Molecular Identifier (UMI), < 250 detected genes, < 80% genes detected per UMI and > 20% mitochondrial genes were excluded. The filtered datasets were normalized and transformed using SCTransform and integrated based on weighted nearest neighbor analysis to produce a unified array for comparative study. To identify major cell types in the skin biopsies, cell clustering was performed with a resolution parameter of 0.1. Skin fibroblasts which were identified using signature genes (LUM, CFD, DCN, VIM, PDGFRA, and COL1A2) from previous studies, were selected and examined at a higher resolution parameter of 1 to reveal the fibroblast subpopulations. UMAP plots of fibroblasts from nondiabetic (n = 4680 cells) and diabetic samples (n = 19954 cells) were constructed based on non-linear dimensional reduction. The selected cells were validated with the Blueprint and ENCODE databases using Celldex, to confirm their fibroblast phenotype. Each subpopulation was annotated based on the published signature genes. The FindMarkers function was used to identify the differentially expressed genes (DEGs) between different subpopulations. GSEA was used to examine the mechanotransduction capability using a curated gene set. Surface markers of the fibroblast subpopulations that are potentially mechanosensitive were shortlisted for validation based on the following criteria : a membrane protein, highly expressed (log 2-fold change > 2 relative to other subpopulations), and specific (expressed in > 50% of the selected subpopulations and < 30% in others). Pseudotime analysis was performed using Monocle3 to map out the cell developmental trajectory with the mesenchymal subtype as the origin.
[0264] RT-qPCR analysis
[0265] Gene expressions under indicated mechanical stimulation and specific treatment were examined using RT-qPCR analysis. Briefly, total RNA was extracted and isolated with RNeasy Plus Mini kit (#74134, QIAGEN). The RNA concentration was checked by nanodrop spectrophotometer (ND-1000-UV / Vis, NanoDrop Technologies), and after standardization, synthesis of cDNA from the obtained RNA was done using iScript cDNA Synthesis Kit (#1708891, BIORAD) by performing the following reaction protocol on thermal cycler (#4359659, Applied Biosystems) : Priming for 5 min at 25°C, reverse transcription for 20 min at 46°C, reverse transcriptase inactivation for 1 min at 95°C, and finally storage at 4oC. For RT-qPCR experiment, SsoAdvanced Universal SYBN Green Supermix (#64443451, BIORAD) was used, and the expression levels of the targeted mRNA transcripts were determined using the StepOnePlus™ Real-Time PCR System (4376600, Thermo Fisher) based on the following protocol : polymerase activation and DNA denaturation at 95°C for 30 s were followed by amplification for 40 cycling stages. Melting curve analysis was conducted by increasing the temperature from 65 to 95°C. The sequence of the respective primers used in this work was obtained from the primer bank (https: / / www.ncbi.nlm.nih.gov / gene / ) as listed in Table SI and synthesized by Integrated DNA Technologies. Target genes transcription levels were analyzed using StepOne Software and calculated by the AACt method, with GAPDH serving as the housekeeping gene.
[0266] For gene analysis on cells from diabetic mice model after desired experiment, the mice skin cells at wound site were first disrupted by liquid nitrogen method. The skin samples were then lysed by TRK Lysis Buffer and cells were collected by RNA homogenizer spin column (omega), followed by general RT-qPCR protocol and primers from the primer bank (https: / / www.ncbi.nlm.nih.gov / gene / ) as listed in Table S2. Target genes transcription levels were analyzed using StepOne Software and calculated by the AACt method, with GAPDH serving as the housekeeping gene.
[0267] Western blot analysis
[0268] Western Blot was used to analyze the protein levels in cells after indicated mechanical stimulation and specific treatment. Briefly, RIPA buffer (abl56034, Abeam) supplemented with protease inhibitor (ab274282, Abeam) was used to extract protein from encapsulated cells in the hydrogel and protein concentration was measured by Micro BCATM Protein Assay Kit (#23235, Thermo Fisher). The extracted protein was mixed with Laemmli Sample Buffer (1610747, BIORAD) supplied with 2-Mercaptoethanol (M3148, Sigma-Aldrich) and heated for 5 minutes for protein denaturation. The protein solution was then added to Mini-protein stain-free precast gels (10 well, 4-20%; 456-8094, BIORAD) and marked by Precision Plus Protein Dual Color Standards (1610374, BIORAD). The gel was run at room temperature at 120 V, powered by PowerPac Basic (BIORAD), and then transfer to protein from the gel to the PVDF transfer membrane (#88518, Thermo Fisher) at 4°C at 10 mA overnight. After blocking at room temperature for 1 hour, the membrane was then incubated according to standard protocols which contained 4-hour primary antibody and 1-hour secondary antibody (horseradish peroxidase labeled) incubation at room temperature. Furthermore, to indicate the boost of Ras / MEK / ERK pathway, U0126 (MEK inhibitor, 10 pM, S1901, Beyotime) was used to verify the effect of mechanical stimulation and co-culture. After the membrane was stained by PierceTM ECL Plus Western Blotting substrate (#32134, Thermo Fisher), the images were taken by CCD camera-based imager (Universal Hood III, BIORAD) and the band intensity was analyzed by Image Lab (Version 5).
[0269] Flow cytometry
[0270] To assess the possibility of TMP leakage from hydrogel construct, fluorescent thiol-coated magnetic particle was used and analyzed by flow cytometer (CytoFLEX LX B-R-V-Y-U-I, Beckman Coulter). On day 28, the medium surrounding hydrogels (with and without mechanical stimulation) were collected and tested to quantify the percentage of fluorescent TMPs in the surrounding solution of gel. The positive control (diluted TMP contained solution) was used to gate for side scatter and fluorescence intensity.
[0271] To confirm whether the cell-loaded hydrogel system will induce any pro- / anti- inflammatory response, an in vitro macrophage polarization assay was conducted by flow cytometry (CytoFLEX LX B-R-V-Y-U-I, Beckman Coulter), which non-activated subset (MO) polarized into pro-inflammatory (Ml) or anti- inflammatory (M2) subset. Briefly, RAW 264.7 cell was co-cultured in 24 well- plate with hydrogel constructs. Three different conditions, including pure PEGDA-RGD-TMP hydrogel, fibroblasts / keratinocyte-loaded PEGDA-RGD-TMP hydrogel, and fibroblasts / keratinocyte-loaded PEGDA-RGD-TMP hydrogel with indicated magnetic stimulation, were conducted. To confirm macrophage polarization, Ml or M2 polarization positive groups were also conducted that the cells were cultured with 400 ng / mL Lipopolysaccharide (LPS) or 100 ng / mL Interleukin-4 (IL-4), respectively. After 3-day culture, stimulated cells were collected and rinsed by PBS twice. After blocking in 1% bovine serum albumin solution (BSA, SH30574.02, HyClone) for 1 hour, anti-mouse CD86 antibody (1 : 100, 105113, Biolegend) and anti-mouse CD206 antibody (1 : 100, 141710, Biolegend) were added and incubated in ice for 30 min. Followed by washing twice with PBS, the cell polarity was measured by flow cytometry.
[0272] To understand cell migration from hydrogel to wound site (mice model), live mice fibroblast / keratinocyte were fluorescently labelled by CellTrace™ CFSE (#C34570, Invitrogen) and measured by flow cytometry (Due to low %migrated cells, flow cytometry was considered as a better approach than microscopic imaging for higher precision and sensitivity). Briefly, fluorescently labelled cells are encapsulated in the hydrogel and attached on the wound site. After desired MDMS, mice skin wound tissues were harvested and rinsed by PBS to remove supernatant cells, and digested using Opti-MEM containing Liberase (0.1 mg / mL; #5401119001, Roche), collagenase (1 mg / mL; #C0130, Roche), and hyaluronidase (#H3884, Merck) at 37oC for 1 h. The blood cells in the samples were lysed by RBC lysis buffer (#420302, Biolegend) and rinsed by PBS. The live and dead cells were identified by Zombie Violet Fixable Viability Kit (#423114, Biolegend) and then analyzed by flow cytometry.
[0273] To separate subpopulations of primary human fibroblast to verify the results, cells were sorted by flow cytometry (Moflo Astrios Sorter, Beckman Coulter), supported by NUS Flow Cytometry Laboratory. Briefly, after trypsinized and washed by staining buffer (PBS + 2% FBS), cells were stained by surface marker, CD55 (1 pg / million cell, sc-51733-PE, Santa Cruz), and separated into CD55 low and high positive groups. Cells without sorting (i.e., the mixture of low and high CD55 positive groups) were served as control group.
[0274] Immunofluorescence staining
[0275] For in vitro experiments, immunofluorescence staining was used to characterize cell phenotype and biomolecule / protein expression. Briefly, after indicated mechanical stimulation or specific treatment, cell-laden hydrogel was first rinsed with PBS twice and fixed in 10% formaldehyde solution (#47608, Sigma- Aldrich) at room temperature for 1 hour. Gels were then rinsed quickly with washing buffer (P0106, Beyotime) and blocking by blocking buffer (P0102, Beyotime) at room temperature for another 1 hour. Following which, the gel was then stained according to standard immunofluorescence staining protocols which contained 2-hour primary antibody incubation and 1-hour secondary antibody staining at darkness. All samples were imaged by confocal microscope (LSM710, Zeiss), and the fluorescent intensity was analyzed by Image!.
[0276] Measurement of blood glucose
[0277] To study the effect of insulin release by MDMS, for all mice, blood samples were obtained from the tail vein after desired MDMS. The blood glucose levels were tested using a blood glucose test meter (Johnson & Johnson) and the corresponding insulin release profiles were analyzed.
[0278] Histology
[0279] At the desired treatment length of diabetic wounds (day 7 and 14), wound tissues were harvested with a punch biopsy tool and maintained in 4% paraformaldehyde for histological studies (n = 10). In this work, samples were then embedded in paraffin and cut into 5-pm sections for storage and further characterization. After deparaffinization and rehydration, hematoxylin and eosin (H&E) and Masson's trichrome (MT) staining were performed, to analyze wound- healing effect, reepithelization, and collagen deposition. Digital images of stained slides were obtained using Vectra Automated Quantitative Pathology Imaging System (PerkinElmer) and quantified using ImageJ. Immunofluorescent staining including F4 / 80 (ab6640, Abeam), o-SMA (abl24964, Abeam), Ki67 (abl5580, Abeam), iNOS (abl 15819, Abeam), Arginase-1 (936685, Cell Signaling), and several secondary antibodies (all from Abeam) were used to explore neovascularization, re-epithelization, cell proliferation, and local inflammation (i.e., M2, Ml percentage), which were analyzed by LAS X and ImageJ software.
[0280] Statistical analysis
[0281] All experimental data were reported as the mean standard deviation, data presentation and sample sizes were presented as indicated in figure captions. Significance was measured as indicated with T-test or one-way ANOVA followed by pairwise comparison with Tukey's multiple comparisons test using Origin (Version 9) and SPSS statistical software (Version 26). Single asterisk (*) indicates p < 0.05, double asterisks (**) indicates p < 0.01, triple asterisks (***) indicates p < 0.001, and quadruple asterisks (****) indicates p < 0.0001.
[0282] Example 1: Design and characterization of biocompatible magneto- responsive hydrogels
[0283] PEGDA-based hydrogels are widely used in biomedicine, and because of its superior in vivo biocompatibility, stability and non-biodegradable feature, it has been used in FDA-approved soft implant (e.g., biosensor products). In this disclosure, PEGDA monomer was synthesized from high molecular weight poly(ethylene glycol) (Fig. 2). To improve hydrogel biocompatibility and cell spreading for mechano-transduction, acrylated RGD motif was introduced into PEGDA polymer chain by ene reaction, and successful introduction was determined by enhanced intensity of RGD fluorescent compounds (Fig. 3A).
[0284] To endow hydrogel with magneto-responsive property, magnetic particles coated with thiol groups (TMP) were incorporated into hydrogel network (i.e., PEGDA-RGD-TMP). Under UV irradiation, PEGDA-RGD-TMP liquid precursor solution swiftly transitioned into a solid gel (Fig. IB), enabling its injectable use for irregularly shaped wounds (Fig. 3B). The gel stiffness (0.3-50 kPa) could be tuned by adjusting polymer mass concentrations and UV exposure time (Fig. 3C). Instead of physical blending TMPs into the hydrogel which might lead to leakage and cytotoxicity, TMPs were grafted onto PEGDA backbone by thiol-ene click reaction as confirmed by the appearance of carbon-sulfur chemical bond (Fig. 3D) to minimize TMP leakage (< 0.5%, Fig. 1C). Large-size TMPs with average diameter of ~3.5 pm were also used (Fig. 3E) to widen the force range of mechanical stimulation while minimizing nanomaterial-associated cytotoxicity from unwanted endocytosis. The magneto-responsiveness and superparamagnetic properties of PEGDA-RGD-TMP hydrogel were confirmed by superconducting quantum interference device (SQUID) analysis (Fig. ID and Fig. 3F). PEGDA-RGD-TMP hydrogel showed excellent stability (i.e., low degradation rate and swelling ratio) with minimal change in physical size / shape and elasticity even under magneto-mechanical perturbations (Fig. IE and Fig. 3G). Considering abnormal pH conditions at diabetic wound sire (pH 6.2-8.5), gel biostability was examined in acidic and basic environment, and it was found that PEGDA-RGD-TMP hydrogel construct was extremely stable at pH 5.0 and 9.0 for at least 4 weeks (Fig. 3H). PEGDA-RGD-TMP hydrogels also had uniform microparticle distribution (Fig. IF), with an interconnected microporous network similar to ECM to provide ample space for nutrient diffusion, cell growth and migration (Fig. 1G and Fig. 4). Notably, with interconnected microporous structure and pore size, there was a well-distributed oxygen level in the hydrogel tested using oxygen fluorogenic probes.
[0285] Dermal fibroblasts (FBs) and epidermal keratinocytes (KCs) are skin cells which perform vital roles including ECM deposition, skin regeneration, and growth factor secretion to facilitate diabetic wound healing. They are also the only cell types that have been approved by the FDA for use in wound treatments. Both cell types and TMPs were homogenously distributed in the hydrogel (Fig. 5). The choice of using relatively large size TMPs minimized endocytosis by cells. The microporous hydrogel network facilitated cell growth with fibroblasts exhibiting spreading morphology and keratinocytes preferring to grow into cell colonies (Fig. 1H). The biocompatibility of the hydrogel was further supported by live / dead assays showing > 90% cell viability (Fig. 6A) and excellent cell metabolism (Fig. 6B-C). Crucially, the hydrogel utilizes low-cost, biocompatible ingredients that are readily available in GMP-grade equivalents, paving the way for future clinical-grade manufacturing.
[0286] Medical devices such as NPWT providing mechanical stimulation are correlated with better wound healing by inducing fibroblast cell division and migration, and the secretion of growth factors. Recent works have also reported the mechano- responsive features of both fibroblasts and keratinocytes. Nevertheless, applying mechanical forces directly to wounded tissues can cause discomfort / pain, induce anxiety, and are limited to superficial skin tissue layers. This limitation can, however, be overcome using a PEG hydrogel incorporating TMPs, hence enabling the material to provide mechanical stimulation to encapsulated cells under a magnetic field (Fig. II). A strong permanent magnet (1.0 T) was attached to a rotating robot for stimulating cells with a low, non- heat generating frequency (0.1 Hz). As the intensity of magnetic field is inversely proportional to the distance between the magnet and hydrogel, when the magnet is cyclically moved closer and further from the hydrogel, TMPs covalently bonded to the PEGDA network would be attracted and released, resulting in the cyclic mechanical stimulation (Fig. 1J and Fig. 7).
[0287] Example 2: Mechano-regulation of cell growth and ECM deposition
[0288] The expression of nuclear proliferation marker, KI67, was used to investigate the effects of MDMS on proliferation of fibroblasts and keratinocytes. There was a higher positive rate of Ki67 (~68%) in fibroblast as compared to keratinocytes (47%) when the cells were cultured and mechanically stimulated separately. In the co-culture system, 3 days of MDMS induced ~200% and ~25% increase in fibroblast and keratinocyte proliferation, respectively (Fig. 2A and Fig. 9). This could be attributed to MDMS activating and inducing nuclear translocation of Yes-associated protein (YAP), which is a well-known transcriptional coactivator for cell mechano-transduction. Upon nucleartranslocation, YAP could upregulate gene expression and promote cell proliferation by the induction of Ki67 (Fig. 2B and Fig. 10) and shift fibroblast population into a 'pre-activated' phenotype. MDMS did not cause obvious change in keratinocyte numbers (Fig. 9B), possibly because this cell type exhibited a rounded morphology unlike fibroblasts which spread more (i.e., with larger surface area and branched structure) and would hence be more sensitive to mechano-stimulation. Interestingly, in the co-culture system, both cell types showed increased Ki67 expression even in the absence of mechano-stimulation. This highlights the importance of using both cell types with distinct functions for wound therapy and suggests the potential of mechanically stimulating fibroblasts and exploiting their coupled communications with keratinocytes to extend the control of a mechanical 'rheostat' indirectly.
[0289] Fibroblasts were found to exhibit a force-dependent expression of Ki67 (Fig. 2C), with stronger magneto-mechanical forces leading to higher proliferation rate. Among the different stimulation durations, 3 days of stimulation led to the highest positive rate of Ki67 (~68%), while the value gradually dropped on day 5 (~50%) and day 7 (~38%) (Fig. 2D). This could be attributed to cell adaption to mechanical stimulation at the same strength and / or exhaustion from higher than normal proliferation rate. One way to overcome the effects of cell adaptation and / or exhaustion would be to use stronger forces, but this would be limited practically by the physical footprint and safety considerations of powerful magnetic devices in clinics or homes. A better way would be to suspend stimulation transiently and allow cells to naturally restore their mechano- sensitivity. Hence after 3 days of MDMS, stimulation was suspended for 7 days before restarting stimulation for 3 additional days. This cell culturing regimen restored Ki67 positive rate from ~21% to ~59% (Fig. 2E) demonstrating the promise of using mechanical force as a switch to regulate cell activation and overcome cell adaptation and / or exhaustion. Compared to methods like chemo- / opto- / acousto-genetics to modulate cell functions, the present method does not require gene transfection which complicates cell manufacturing and regulatory approvals, and any use of invasive and costly devices like optic fiber and ultrasound machine that dissuades clinical use.
[0290] Changes in ECM such as lower levels of collagen type I resulting from reduced fibroblast proliferation and migration is a factor contributing to poor healing rate and recurrence in diabetic wounds. MDMS was found to improve collagen deposition by fibroblasts, leading to more extensive and denser collagen network in mechanically stimulated hydrogel (Fig. 2F and Fig. 11). A ~2.5-fold upregulation was observed for collagen type I (COL1A1) gene by RT-qPCR, independent of higher fibroblast cell number, supporting that mechanically stimulated fibroblasts secreted more collagen (Fig. 2B).
[0291] Example 3: Angiogenic effects of mechano-controlled cell secretion
[0292] Poor circulation caused by compromised vascular integrity around diabetic wounds limits nutrient transport to and removal of metabolic waste products from the wound site. This is known to induce senescence of fibroblasts and keratinocytes around the wound and induce a vicious cycle of reduced local secretions of pro-angiogenic factors like vascular endothelial growth factor (VEGF) which worsen angiogenesis and wound healing.
[0293] Studies have shown that both loaded cell types, particularly keratinocytes, can secrete VEGF. Here, the effects of MDMS on VEGF secretion was examined in a fibroblast / keratinocyte co-culture system and found that stronger and longer stimulation enhanced VEGF production measured using ELISA (Fig. 12A-B). VEGF production was also higher in a mechanically stimulated co-culture system compared to having only either cell type. When keratinocytes were treated with conditioned media of mechanically stimulated fibroblasts, there was a significant increase in VEGF production, but not the other way round (Fig. 12C). This data is aligned with the observation that fibroblasts were more sensitive to mechanical stimulation and after mechanical activation, they could induce keratinocyte activation to produce more VEGF through direct cell-cell contact and / or indirect activities such as paracrine secretions.
[0294] To identify possible biological pathways in keratinocytes responsible for higher VEGF secretions, we focused on a number of relevant genetic candidates such as nuclear proliferation gene (MKI67), inflammation and hypoxia related genes (MMP9 and HIF1A), regulatory gene of VEGF (FOXO1), and genes in the Ras / MEK / ERK pathway. A notable increase in the transcription factor MAPK implies the involvement of the Ras / MEK / ERK pathway. In this process, the upstream protein Ras activates MAPK / ERK kinase (MEK), which phosphorylates extracellular signal-regulated kinases 1 and 2 (ERK1 / 2 to p-ERKl / 2). This, in turn, leads to the upregulation of VEGF expression (Fig. 12D). We further showed that MDMS upregulated the protein levels of Ras and p-ERKl / 2, leading to the increased VEGF production (Fig. 12E). Suspension of MDMS reduced the protein levels of Ras, p-ERKl / 2 and VEGF and could be restored after MDMS was restarted (Fig. 12F), demonstrating the power of using our hydrogel system like a mechano-stat to modulate VEGF production by keratinocytes indirectly through mechanically activated fibroblasts. The addition of U0126, an inhibitor of MEK reduced the protein levels of p-ERK and VEGF but not Ras, further supporting the involvement of Ras / MEK / ERK pathway (Fig. 13).
[0295] With the data from ELISA and RT-qPCR, it is proposed in Fig. 12G that a potential pathway in which MDMS primarily activates encapsulated fibroblasts via the YAP pathway. Activated fibroblasts then potentiate VEGF production by co-cultured keratinocytes via the Ras / MEK / ERK pathway. In other words, in this co-culture hydrogel system, fibroblast acts as the mechanical 'transducer' of external mechanical cues to activate keratinocytes. The conditioned media of fibroblast / keratinocyte co-culture system under MDMS most significantly improved endothelial cell proliferation rate (Fig. 12H), angiogenic sprouting (Fig. 121 and Fig. 14), migration (chemoattractant activity, Fig. 12J and Fig. 15), and tubulogenesis (tubular network formation, Fig. 16). Collectively, these results highlight the promise of harnessing the power of wireless magneto-mechanical stimulation to enhance VEGF secretions so as to promote angiogenesis and restore healthy blood circulation at diabetic wound sites.
[0296] Example 4: Selective activation of mechano-sensitive fibroblasts
[0297] The advent of single cell RNA sequencing (scRNAseq) has enabled researchers to identify sub-populations of cells with unique properties most suitable for targeted applications such as more targeted cell types for CAR-T immunotherapy. As fibroblasts were found to exhibit greater mechano- sensitivity to MDMS than keratinocytes in former data, the therapeutic efficacy of the present platform may be further amplified by using a fibroblast sub- population that is enriched for mechano-sensitive properties. Leveraging on publicly accessible single-cell dataset of human forearm skin biopsies, it was identified that human skin-derived fibroblasts comprised of five subpopulations, namely, mesenchymal, secretory-reticular, secretory-reticular / papillary, secretory-papillary and proinflammatory fibroblasts, and these were consistently found in nondiabetic (healthy) and diabetic individuals (Fig. 17A). These five subpopulations have distinct gene signatures (Fig. 17B), demonstrating cell heterogeneity and potential therapeutic impact of identifying, characterising, and using the most suitable sub-population for wound healing applications. Diabetic patients had fewer mesenchymal (8.27% vs. 19.12%) and secretory-reticular (31.15% vs. 37.95%), higher secretory- reticular / papillary (21.52% vs. 11.05%) and secretory-papillary (21.56% vs. 12.07%), and comparable proinflammatory fibroblasts (17.49% vs. 19.81%) in their forearm skin than non-diabetic individuals. Except for secretory- reticular / papillary subpopulation, four out of the five subpopulations have been previously reported. Conceivably, the secretory-reticular / papillary fibroblast is an intermediate cell type between secretory-reticular and secretory-papillary fibroblasts due to the high overlap of signature genes from both subpopulations (Fig. 17B). This postulation is in line with the Pseudotime analysis (Fig. 18) which revealed only three major lineages (i.e., secretory-reticular, secretory- papillary, and proinflammatory) originated from mesenchymal fibroblast.
[0298] To investigate the mecha no-sensitivity of the fibroblast subpopulations, the enrichment of a mechano-transduction gene set was examined in the transcriptomes of the five fibroblast subpopulations challenged with biochemical stimuli and mechanical tension. The Gene Set Enrichment Analysis (GSEA) suggested that the secretory-papillary and secretory-reticular fibroblast are potentially mechano-sensitive, as indicated by the positive normalized enrichment scores in both the nondiabetic and diabetic samples (Fig. 17C). While the secretory-papillary fibroblast sub-population exhibited the highest mechano-sensitivity, its low cell population percentage (~10% in healthy donor, ~23% in diabetic patient) may limit manufacturing scalability for downstream clinical use. On the other hand, secretory-reticular fibroblast (~40% in healthy donors, ~34% in diabetic patients) was a more abundant cell source (Fig. 17A) and its transcriptome is linked to cytoskeleton reorganization and ECM macromolecule synthesis which are closely associated with ability to detect and translate mechanical signals.
[0299] Next, differential expression analysis was performed using a pooled cellular population comprising of secretory-reticular fibroblast subpopulation to identify surface markers that are overexpressed in them. Using a set of stringent criteria as described in the methods, 6 potential surface markers, including CD55, AKCR3, GALNT15, SYT1, ENTPD1, and DPP4 were shortlisted. CD55, a complement decay-accelerating factor and a membrane protein, was significantly overexpressed (log 2-fold change = 6.76; FDR = 7.95 x 10132) in the putative mechano-sensitive fibroblast subpopulations, especially the secretory-reticular fibroblast in both nondiabetic and diabetic tissues (Fig. 17D). Hence, CD55 was selected as targeted surface biomarker to sort primary human-derived fibroblasts with low and high CD55 expressions. Primary human-derived secretory-reticular fibroblasts showed higher expression of YAP1 under MDMS (Fig. 17E), indicating that this subpopulation was more mechano- sensitive. In addition, compared to fibroblasts with 'low CD55 expression', 'MDMS better promoted collagen secretion and cell proliferation by fibroblast with high CD55 expression (Fig. 17F). As expected, mechano-stimulation enhanced proliferation of primary human dermal fibroblasts (1.3-fold increase of cell number with higher nuclei positive rate of YAP and Ki67, Fg. 19A) and VEGF secretions by human primary epidermal keratinocytes (Fig. 19B). By leveraging scRNAseq data, we demonstrate the possibility to isolate a more mechano-sensitive subpopulation of fibroblast to maximize the therapeutic impact of magneto-responsive hydrogel and MDMS.
[0300] Example 5: Enhanced biomolecule release and cell migration with mechano-stimulation
[0301] Magneto-mechanical stimulation can provide directional hydrogel deformation to enhance interstitial flow within the material, improve cell migration, and accelerate drug release from hydrogel (Fig. 20A). This feature is particularly promising for on-demand release of cell secretome including VEGF and therapeutic drugs like insulin to regulate blood glucose level locally at wound sites with poor blood circulation.
[0302] The ability of MDMS for controlled delivery of insulin was first investigated as insulin is a critical biomolecule with a short half-life that requires fast release and it regulates local glucose environment to influence the rate of wound healing. Recent studies highlighted the importance of regulating blood glucose levels around wound area as hyperglycemia decreases cell recruitment and activation needed for tissue regeneration. Multiphysics modeling showed that MDMS induced larger deformation and movement of hydrogel network, generating interstitial flow with higher diffusion and exchange rate of loaded insulin molecules (Fig. 20B and Fig. 21). This result was supported by ELISA, as shown in Fig. 20C and Fig. 22A, where MDMS accelerated insulin release from the gel to its surrounding environment in a force-dependent manner.
[0303] Taking advantages of our ON / OFF magnetic control system, we next demonstrated that the release kinetics (i.e., accelerated release or sustained slow diffusion) of insulin could be tuned accordingly (Fig. 20D and Fig. 22B). This feature is helpful to maintain physiologically healthy glucose levels by avoiding excessive insulin delivery and hypoglycemia. This feature was also demonstrated in a diabetic mice model where stronger MDMS induced greater insulin release in vivo as indicated by a more dramatic change in blood glucose level (Fig. 20E). This feature may be exploited to modulate the release of other species of therapeutic molecules with antimicrobial and anti-inflammation properties.
[0304] The ability of the technology to accelerate cell migration was further examined. While there have been multiple reports on cell encapsulation in biomaterials, none of them has demonstrated the ability to direct cell migration from hydrogel into wound environment which is key for cell recruitment into wounded tissues to accelerate wound closure. MDMS enhanced cell migration out of hydrogel with ~1.5-fold better effects observed for fibroblasts than keratinocytes in vitro (Fig. 20F and Fig. 23). Similar observation was made in an in vivo model showing that there was 7-fold greater migration of fluorescently labeled fibroblasts and keratinocytes from hydrogel into wound sites with stronger MDMS (Fig. 20G and Fig. 24). Overall, the ability of this platform to mechanically modulate drug release and cell migration with different MDMS intensities makes it a powerful technology for spatiotemporal regulation of the wound environment with therapeutic biomolecules and cells.
[0305] Example 6: Mechano-acceleration of diabetic wound healing in vivo
[0306] The therapeutic efficacy of magneto-responsive hydrogel was evaluated using a full-thickness diabetic injury mice model (Fig. 25A). Allogeneic fibroblasts and keratinocytes were encapsulated in PEGDA-RGD-TMP hydrogel and applied on the back wound as a form of dressing, serving as a 'bandage'. The '3Day / 20mm' treated group showed the fastest wound closure rate (92.7 ± 6.7%) compared to other conditions, treated mice in this group were almost covered with newly formed skin on day 14 (Fig. 25B-C). It is worth noting that the high water content of hydrogel likely reduced scab forming during wound healing which is in agreement with the theory of 'moist wound healing'.
[0307] We first evaluated the progress of wound healing by hematoxylin and eosin (H&E) staining on day 7 and 14 (Fig. 25D). There was more abundant and thicker granulation tissue with shorter unhealed length of wound bed observed in '3Day / 20mm' hydrogel-treated wounds on day 7 (Fig. 25E), indicating faster wound re-epithelization. Moreover, from H&E staining results, it could be seen that no hydrogel / TMP retention was observed around wound site due to non- tissue adhesive feature of hydrogel. In comparison to existing adhesive dressings, which can cause secondary damage to delicate wound tissues upon removal due to their non-switchable adhesion, our approach minimizes discomfort during periodic bandage replacement.
[0308] In addition, based on Masson's trichrome (MT) staining on day 7 and 14 (Fig. 25F), more collagen synthesis was observed in the regenerated tissue. As plotted in Fig. 25G, on day 7, wounds of '3Day / 20mm' treated group had ~1.6- fold higher collagen deposition density than that of the control group, likely attributing to better skin cell recruitment from increased paracrine secretion (e.g., growth factor) and increased cell proliferation at wound bed (Fig. 25H-I). Impaired vasculature at wound bed impedes oxygen delivery, creating a hypoxia environment. While acute hypoxia can be beneficial for cell proliferation and initiates tissue repair, long-term oxygen deprivation in wounds inhibits angiogenesis of capillaries that transport nutrients and remove toxic metabolic waste products from wounded tissue. The data shows that there was no hypoxia in the wound bed by O2 characterization and gene expression (Fig. 26) which might otherwise have induced acute angiogenesis. Neovascularization was next evaluated using immunofluorescent staining of o-smooth muscle cells (o-SMA). Out of all different treatment groups, on day 14, only the '3Day / 20mm' hydrogel group exhibited extensive vasculature throughout the entire wound, with high a-SMA intensity and well distributed network of mature blood vessels (Fig. 25H,J). In contrast, the other treatment groups had noticeably more of their re- vascularization occurring proximal to the wound edges. This was further confirmed by H&E and MT staining which showed more capillary vasculatures (e.g., lumen structure) as indicated by the red stains in '3Day / 20mm' groups than in other groups. The greater angiogenic effect was likely due to MDMS- induced VEGF production and magneto-accelerated release.
[0309] During the whole treatment, none of the wounds showed obvious sign of infection, and the hydrogel and external magneto-induced stimulation led to negligible inflammation which was confirmed by the bulk tissue gene expression of immune response signals (i.e., inflammatory mediators) (Fig. 27) and polarization / phenotype of wound tissue macrophages (i.e., M2, Ml percentage) (Fig. 28). Across all groups, there was a similar ratio of M1 / M0 and M2 / M0 macrophage polarization.
[0310] Gene expression data strongly supported tissue histology observations (Fig. 27). Using a library of the most relevant genes associated with wound healing, we found that across the different groups, conditions using the 'Hydrogel+MDMS+Cell' strategy clearly showed an up-regulation of genes involved in tissue regeneration including EGR1 and MFGE8. There were also elevated gene expression levels of multiple key pro-angiogenic and pro-healing growth factors supporting better cell proliferation and recruitment, namely VEGFA, FGF2, and EGF, aligned with former in vitro data. Matrix metalloproteinases (MMP2 / 9), which are known to play critical roles in ECM remodeling and recruitment of endothelial cells for neovascularization, were significantly up-regulated in response as well. With that, we observed an increase in TIMP (tissue inhibitor of metalloproteinase), an important inhibitor of MMPs produced by basal keratinocytes, in '3Day / 20mm' hydrogel-treated wounds. This demonstrated that a homeostatic balance between MMPs and their inhibitors was achieved, reflective of active remodeling of wounds in a more mature stage. Finally, across all groups, there were similar levels of gene expressions related to inflammation, supporting that our material is biocompatible and that the strategy of using a cell biofactory bandage could also minimize unwanted inflammation.
[0311] Finally, in vivo biosafety was demonstrated by organ H&E staining showing no adverse reaction in major organs (Fig. 29), aligned with excellent cell metabolism (Fig. 30) and blood compatibility (hemolysis ratios = 0.66% < 5%, indicating hemocompatibility).
[0312] Example 7: Discussion
[0313] Diabetic wounds are a significant global healthcare challenge. They are difficult to treat due to the complexity of diabetes as a metabolic disorder and its associated wounds harbor multiple pathological factors such as a high glucose environment, inactivation of surrounding cells, compromised vessel system, damaged ECM network, and low-grade chronic inflammation. These abnormalities often interact and reinforce one another, creating a vicious cycle that impedes wound healing. To effectively treat diabetic wounds, a strategy that targets multiple pathological factors was developed. The present disclosure integrates the unique therapeutic properties of magneto-responsive hydrogel, cells, and controllable drug delivery.
[0314] MDMS was utilised to mechanically regulate the functions of encapsulated cells to improve cell proliferation, ECM deposition, VEGF production, cell migration, and wound closure simultaneously. It was found that while both fibroblast and keratinocyte cell types are mechanosensitive, mechanical stimulation preferentially activated fibroblasts that adhered strongly to RGD motifs and displayed a spreading morphology in contrast to keratinocytes which preferred to grow in colonies. MDMS-activated fibroblasts functioned as "feeder" or "messenger" cells, integrating and transforming mechanical cues to regulate keratinocyte activity including the production of VEGF (Fig. 12G). Our study supports the symbiotic relationship of both cell types and the use of both cell types for wound treatment products such as in FDA-approved product StrataGraft® which is an allogeneic fibroblast and keratinocyte product for deep partial-thickness burns.
[0315] The present disclosure leverages mechano-responsive material design to selectively activate a sub-population of mechano-sensitive fibroblasts identified with scRNAseq database to maximize therapeutic impact. In particular, we created a material that functions like a mechano-rheostat to tune the functions of mechano-sensitive fibroblasts including suspension and re-activation of metabolic activities. Learning from the experience of CAR-T therapy, such control could be clinically valuable to maximize therapeutic outcomes by preventing cell senescence / exhaustion, and enhance safety through ON / OFF spatiotemporal regulation of cell states. Although chemo-genetics, optogenetics and acousto-genetics may be used to control cell function, these methods require an additional step of cell transfection which complicates cell manufacturing, has low efficiency for primary fibroblasts and require invasive or bulky devices like optic fibers and ultrasound machines. In contrast, the magnetic hydrogel system offers a distinct advantage by achieving significant and reversible cell control without further genetic editing. This concept can be applied to other disease treatments and guide the design of biomaterials for synergistic use with cell therapy in clinics.
[0316] The present magnetic hydrogel system is advantageous in a few ways for mechanically regulating the activity of encapsulated fibroblasts and keratinocytes. First, the system enables spatiotemporal control of cellular activity and drug release to address multiple pathological features of diabetic wounds using a single technology platform (Fig. 31). In the present disclosure, there is a mechanistic understanding of the interactions between mechanically activated fibroblasts and co-cultured keratinocytes via the Ras / MEK / ERK pathway. This would enable optimization of stimulation conditions to achieve even better wound healing rate. Second, MDMS can be provided in a clinical setting using external magnetic fields with a commercially available magnet without side effects or damage to surrounding cells and discomfort and pain that come from physically stretching the wounded skin. Third, the hydrogel system requires relatively low cell numbers (1 x 106cells / mL versus 2 x 107cells / mL in FDA-approved product LAVIV®), which reduces manufacturing time and costs. Allogenic or epigenetically reprogrammed cell sources which are under active investigations may even be used in the future to ease clinical translation. Fourth, the ingredients of the hydrogel are low-cost and biocompatible, with commercially available FDA-approved equivalents.
[0317] Clinically, MDMS can be provided using commercially available neodymium magnets without side effects or damage to surrounding cells and discomfort and pain that from physically stretching the wounded skin. Importantly, unlike emerging wearable electronics that provide electrical stimulation to promote tissue regeneration, the present approach does not require batteries. Additionally, most wearable electronics depend on exogenously loaded growth factors, cytokines, antibiotics, and insulin to generate therapeutic effects, but these molecules get depleted quickly and their in vivo degradation rates vary substantially from patient-to-patient, thus necessitating frequent and expensive change in electronic dressings. On the other hand, these limitations are not associated with the use of magnets for MDMS;
[0318] All in all, the present hydrogel synergistically integrates the strengths of smart biomaterials, co-culture cell systems and tunable mechanical stimulation to treat diabetic wounds and other challenging wound types. Clinically, the hydrogel may be applied as part of a routine dressing and patients would have the option of performing MDMS at the comfort of their homes using a portable magnetic system. Such a non-invasive approach is increasingly popular as seen in the uptake of portable wound care devices including acoustic shockwave therapy (e.g., PACE®) and subsensory electrical pulse therapy (e.g., Accel- Heal®) that patients can self-administer safely at home.
[0319] The concept of biomaterial-mediated mechano-regulation of cells for therapy may also be exploited for other FDA-approved cell types like stem cells and CAR-T cells to maximize therapeutic efficacy and safety, and for large animal models, humanized mice with human explant tissues and human trials. Table SI. Primer sequence of genes used in human skin cell RT-qPCR studies.
[0320] Homo Gene Primer Sequence (5'->3')
[0321] MKI67 F: GGATCGTCCCAGTGGAAGAG (SEQ ID NO: 1)
[0322] R: CAAACAAGCAGGTGCTGAGG (SEQ ID NO: 2) COL1A1 F: CCCCGAGGCTCTGAAGGT (SEQ ID NO: 3)
[0323] R: GCAATACCAGGAGCACCATTG (SEQ ID NO: 4)
[0324] FN1 F: CCGCCGAATGTAGGACAAGA (SEQ ID NO: 5)
[0325] R; TGTCAGAGTGGCACTGGTAG (SEQ ID NO: 6)
[0326] YAP1 F: GAACTCGGCTTCAGCCATGA (SEQ ID NO: 7)
[0327] R: CTGCCGAAGCAGTTCTTGC (SEQ ID NO: 8)
[0328] FOXO1 F: AGGGTTAGTGAGCAGGTTACAC (SEQ ID NO: 9)
[0329] R: TGCTGCCAAGTCTGACGAAA (SEQ ID NO: 10)
[0330] MAPK F: ATCTTAAATTTGTCAGGACAAGGG (SEQ ID NO: 1 1)
[0331] R: CAAACGGCTCAAAGGAGTCA (SEQ ID NO: 12)
[0332] HIF1A F: AGTGTACCCTAACTAGCCGAGGAA (SEQ ID NO: 13)
[0333] R: TACCCACACTGAGGTTGGTTACTG (SEQ ID NO: 14)
[0334] MMP9 F: CTTTGAGTCCGGTGGACGAT (SEQ ID NO: 15)
[0335] R: TCGCCAGTACTTCCCATCCT (SEQ ID NO: 16)
[0336] GAPDH F: CCACTAGGCGCTCACTGTTC (SEQ ID NO: 17)
[0337] R: CCCAATACGACCAAATCCGTTG (SEQ ID NO: 18) Table S2. Primer sequence of genes used in mice skin cell RT-qPCR studies.
[0338] Mouse Gene Primer Sequence (5'->3') _
[0339] YAP1 F: GTGGAGGCAGTTCCAACCAG (SEQ ID NO: 19)
[0340] R: ATTCCGTATTGCCTGCCGAA (SEQ ID NO: 20)
[0341] MKI67 F: ACCATCATTGACCGCTCCTT (SEQ ID NO: 21)
[0342] R: TTGACCTTCCCCATCAGGGT (SEQ ID NO: 22)
[0343] EGR1 F: TGAGCACCTGACCACAGAGTC (SEQ ID NO: 23)
[0344] R: TAACTCGTCTCCACCATCGC (SEQ ID NO: 24)
[0345] MFGE8 F: CAACCTAGCCTCCCGTTGTT (SEQ ID NO: 25)
[0346] R: CTCCTTGTCTCCACCGCTTT (SEQ ID NO: 26)
[0347] COL1A1 F: CGATGGATTCCCGTTCGAGT (SEQ ID NO: 27)
[0348] R: CGATCTCGTTGGATCCCTGG (SEQ ID NO: 28)
[0349] COL3A 1 F: AAGGCTGCAAGATGGATGCT (SEQ ID NO: 29)
[0350] R: GAGGGCCATAGCTGAACTGAA (SEQ ID NO: 30)
[0351] FN1 F: GGCCACCATTACTGGTCTGG (SEQ ID NO: 31)
[0352] R: GGAAGGGTAACCAGTTGGGG (SEQ ID NO: 32)
[0353] 1TGB1 F: GGACGCTGCGAAAAGATGAA (SEQ ID NO: 33)
[0354] R: CCACAATTTGGCCCTGCTTG (SEQ ID NO: 34)
[0355] TNC F: AGCTTTCTAGTAACGGTGGTGG (SEQ ID NO: 35)
[0356] R: CTTCCGGTTCAGCTTCTGTAA (SEQ ID NO: 36)
[0357] ELN F: CTGGTGGACCAGGAGTTAGG (SEQ ID NO: 37)
[0358] R: TCCACCTCTGGCTCCGTAT (SEQ ID NO: 38)
[0359] MMP2 F: CCCCATGAAGCCTTGTTTACC (SEQ ID NO: 39)
[0360] R: TTGTAGGAGGTGCCCTGGAA (SEQ ID NO: 40)
[0361] MMP9 F: TCACCATGAGTCCCTGGCA (SEQ ID NO: 41)
[0362] R: AGCGGTACAAGTATGCCTCTGC (SEQ ID NO: 42) TIMP2 F: GACTTCATTGTGCCCTGGGA (SEQ ID NO: 43)
[0363] R: ATGGGACAGCGAGTGATCTTG (SEQ ID NO: 44)
[0364] CTSK F: GACACCCAGTGGGAGCTATG (SEQ ID NO: 45)
[0365] R: ACCACTTCTTCACTGGTCATGT (SEQ ID NO: 46)
[0366] VEGFA F: CGGGCCTCGGTTCCA (SEQ ID NO: 47)
[0367] R: GCAGCCTGGGACCACTTG (SEQ ID NO: 48)
[0368] FGF2 F: GGCTGCTGGCTTCTAAGTGT (SEQ ID NO: 49)
[0369] R: GTCCCGTTTTGGATCCGAGT (SEQ ID NO: 50)
[0370] EGF F: AACAAACACACGGGGAAGGA (SEQ ID NO: 51)
[0371] R: TGAGAAGTTCGGGGTCAGGA (SEQ ID NO: 52)
[0372] PDGFB F: GATCTCTCGGAACCTCATCG (SEQ ID NO: 53)
[0373] R: GGCTTCTTTCGCACAATCTC (SEQ ID NO: 54)
[0374] CTGF F: AGAACTGTGTACGGAGCGTG (SEQ ID NO: 55)
[0375] R: GTGCACCATCTTTGGCAGTG (SEQ ID NO: 56)
[0376] TNFA F: TGAGAAGTTCCCAAATGGCCTC (SEQ ID NO: 57)
[0377] R: CTACAGGCTTGTCACTCGAATTTTG (SEQ ID NO: 58)
[0378] IL6 F: AGCCAGAGTCCTTCAGAGAGAT (SEQ ID NO: 59)
[0379] R: AGGAGAGCATTGGAAATTGGGG (SEQ ID NO: 60)
[0380] IL1O F: ACTGGCATGAGGATCAGCAG (SEQ ID NO: 61)
[0381] R: CTCCTTGATTTCTGGGCCAT (SEQ ID NO: 62)
[0382] ARG1 F: CTCCAAGCCAAAGTCCTTAGAG (SEQ ID NO: 63)
[0383] R: AGGAGCTGTCATTAGGGACATC (SEQ ID NO: 64)
[0384] TBX21 F: CCCATTACCACCTATCCGCC (SEQ ID NO: 65)
[0385] R: GTTCACACACTCCCTGCCTT (SEQ ID NO: 66)
[0386] GATA3 F: GGAGCCCACAAGCCATTACA (SEQ ID NO: 67)
[0387] R: ACATATAAGCGGTTCCCTGGC (SEQ ID NO: 68)
[0388] GAPDH F: AAGGTCGGTGTGAACGGATTTG (SEQ ID NO: 69)
[0389] R: TGTAGTTGAGGTCAATGAAGGGGTC (SEQ ID NO: 70)
[0390] It will be appreciated that many further modifications and permutations of various aspects of the described embodiments are possible. Accordingly, the described aspects are intended to embrace all such alterations, modifications, and variations that fall within the spirit and scope of the appended claims.
[0391] As used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (or).
[0392] As used in this application, the singular form "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "an agent" includes a plurality of agents, including mixtures thereof. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[0393] Throughout this specification and the claims which follow, unless the context requires otherwise, the phrase "consisting essentially of", and variations such as "consists essentially of" will be understood to indicate that the recited element(s) is / a re essential i.e. necessary elements of the invention. The phrase allows for the presence of other non-recited elements which do not materially affect the characteristics of the invention but excludes additional unspecified elements which would affect the basic and novel characteristics of the method defined.
[0394] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Claims
Claims1. A magnetically responsive hydrogel for wound healing, comprising : a) a matrix comprising polymerised polyethylene glycol (PEG) macromonomeric residues crosslinked with magnetic particles; b) cell adhesion motifs covalently bonded to the matrix; and c) dermal and epidermal cells encapsulated within the matrix; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm; and wherein the hydrogel is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
2. The magnetically responsive hydrogel of claim 1, wherein the PEG macromonomeric residues are derived from macromonomeric units comprising two or more unsaturated functional groups selected from the group consisting of methacrylate, acrylate, methacrylamide, acrylamide, norbornene, vinyl sulphone, allyl, vinyl, alkynyl and propiolate.
3. The magnetically responsive hydrogel of claim 2, wherein the PEG macromonomeric units are terminally functionalised with two or more unsaturated functional groups.
4. The magnetically responsive hydrogel of claim 2 or 3, wherein the PEG macromonomeric units are PEG diacrylate (PEGDA) macromonomeric units.
5. The magnetically responsive hydrogel of any one of claims 1 to 4, wherein the PEG macromonomeric residues are characterised by an average molecular weight of about 1000 to about 3000 Da.
6. The magnetically responsive hydrogel of claim 5, wherein the PEG macromonomeric residues are characterised by an average molecular weight of about 2000 Da.
7. The magnetically responsive hydrogel of any one of claims 1 to 6, whereinthe hydrogel comprises about 5% w / w to about 10% w / w of PEG macromonomeric residues relative to the hydrogel.
8. The magnetically responsive hydrogel of any one of claims 1 to 7, wherein the hydrogel has a Young's modulus of about 0.1 kPa to about 1 kPa.
9. The magnetically responsive hydrogel of any one of claims 1 to 8, wherein the hydrogel has a thickness of about 0.5 mm to about 3 mm.
10. The magnetically responsive hydrogel of any one of claims 1 to 9, wherein the magnetic particles are thiol-functionalised magnetic particles.
11. The magnetically responsive hydrogel of any one of claims 1 to 10, wherein the percentage of surface thiol moieties on each magnetic particle is about 0.1% to about 10%.
12. The magnetically responsive hydrogel of claim 11, wherein the percentage of surface thiol moieties on each magnetic particle is about 1%.
13. The magnetically responsive hydrogel of any one of claims 1 to 12, wherein the concentration of magnetic particles in the hydrogel is about 0.5% w / w to about 2% w / w relative to the hydrogel.
14. The magnetically responsive hydrogel of any one of claims 1 to 13, wherein the magnetic particles are homogeneously distributed within the hydrogel.
15. The magnetically responsive hydrogel of any one of claims 1 to 14, wherein the cell adhesion motif comprises a peptide.
16. The magnetically responsive hydrogel of claim 15, wherein the cell adhesion motif is Arg-Gly-Asp (RGD).
17. The magnetically responsive hydrogel of any one of claims 1 to 16, wherein the cell adhesion motif is derived from a cell adhesion motif precursor comprising an acrylate group.
18. The magnetically responsive hydrogel of any one of claims 1 to 17, wherein the cell adhesion motif is covalently bonded to the matrix via a C-C bond, C-S bond, amide bond, or a combination thereof.
19. The magnetically responsive hydrogel of any one of claims 1 to 18, wherein the cell adhesion motif is present at a density of about 0.2% w / w to about 0.6% w / w relative to the hydrogel.
20. The magnetically responsive hydrogel of claim 19, wherein the cell adhesion motif is present at a density of about 0.4% w / w relative to the hydrogel.
21. The magnetically responsive hydrogel of any one of claims 1 to 20, wherein the cell adhesion motifs are homogeneously distributed within the hydrogel.
22. The magnetically responsive hydrogel of any one of claims 1 to 21, wherein the hydrogel comprises about 105to about 107encapsulated cells.
23. The magnetically responsive hydrogel of claim 22, wherein the hydrogel comprises about 106encapsulated cells.
24. The magnetically responsive hydrogel of any one of claims 1 to 23, wherein the ratio of dermal cells to epidermal cells is about 1 : 10 to about 10: 1.
25. The magnetically responsive hydrogel of claim 24, wherein the ratio of dermal cells to epidermal cells is about 1 : 1.
26. The magnetically responsive hydrogel of any one of claims 1 to 25, wherein the hydrogel is a photopolymerised hydrogel.
27. The magnetically responsive hydrogel of any one of claims 1 to 26, wherein the hydrogel is formed from an injectable liquid precursor.
28. The magnetically responsive hydrogel of any one of claims 1 to 27, wherein the one or more biological responses is selected from the group consistingof cell migration, cell proliferation, cell production of extracellular matrix material, and cell secretion of biomolecules.
29. The magnetically responsive hydrogel of claim 28, wherein the one or more biological response is selected from the group consisting of increased cell migration out of the hydrogel, increased cell proliferation, increased production of type I collagen, and increased secretion of vascular endothelial growth factor (VEGF).
30. The magnetically responsive hydrogel of any one of claims 1 to 29, wherein the hydrogel further comprises one or more encapsulated compounds selected from the group consisting of a cytokine, a hormone, a growth factor, an anti-inflammatory compound and an antimicrobial compound.
31. The magnetically responsive hydrogel of claim 30, wherein the hydrogel regulates release of the one or more encapsulated compounds when deformed in the presence of a magnetic field.
32. The magnetically responsive hydrogel of any one of claims 1 to 31, further comprising an adhesive dressing which borders the magnetically responsive hyd rogel.
33. A kit for forming a magnetically responsive hydrogel, comprising : a) polyethylene glycol diacrylate (PEGDA) macromonomeric units; b) magnetic particles each functionalised with thiol moieties; c) cell adhesion motif precursors each comprising an acrylate moiety; and d) dermal and epidermal cells; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm.
34. A liquid precursor of a magnetically responsive hydrogel, comprising : a) polyethylene glycol diacrylate (PEGDA) macromonomeric units; b) magnetic particles each functionalised with thiol moieties; c) cell adhesion motif precursors each comprising an acrylate moiety;and d) dermal and epidermal cells; wherein the magnetic particles are characterised by a particle size of about 1 pm to about 10 pm.
35. The kit of claim 33 or liquid precursor of claim 34, further comprising a photoinitiator.
36. A system for use in wound healing, comprising: a) a magnetically responsive hydrogel of any one of claims 1 to 30; and b) magnetic means for mechanically deforming the hydrogel.
37. The system of claim 36, wherein the magnetic means is capable of generating a magnetic field with a maximum magnetic flux density of about 0.1 T to about 1 T.
38. The system of claim 36 or 37, wherein the magnetic means is capable of generating a periodic magnetic field.
39. The system of claim 38, wherein the magnetic means is capable of generating a periodic magnetic field with a frequency of about 0.1 Hz.
40. A method for stimulating a biological response in a cell, the method comprising: a) encapsulating the cell in a magnetically responsive hydrogel of any one of claims 1 to 32; and b) applying a magnetic field to deform the hydrogel to stimulate one or more biological responses from the encapsulated cells.
41. The method of claim 40, wherein the cell is a dermal or an epidermal cell.
42. The method of claim 40 or 41, wherein the applied magnetic field has a maximum magnetic flux density of about 0.1 T to about 1 T.
43. The method of any one of claims 40 to 42, wherein the applied magneticfield is a periodic magnetic field.
44. The method of claim 43, wherein the applied magnetic field is a periodic magnetic field with a frequency of about 0.1 Hz.
45. A method of treating a wound in a subject in need thereof, the method comprising: a) contacting a magnetically responsive hydrogel of any one of claims 1 to 32 with the wound in the subject; and b) applying a magnetic field to deform the hydrogel to stimulate one or more biological responses from the encapsulated cells.
46. The method of claim 45, wherein the subject is suffering from diabetes mellitus.
47. The method of claim 45 or 46, wherein the wound is a skin ulcer.
48. The method of any one of claims 45 to 47, wherein the encapsulated dermal and epidermal cells are autologous, syngeneic or allogeneic with respect to the subject.
49. The method of any one of claims 45 to 48, wherein the applied magnetic field has a maximum magnetic flux density of about 0.1 T to about 1 T.
50. The method of any one of claims 45 to 49, wherein the applied magnetic field is a periodic magnetic field.
51. The method of claim 50, wherein the applied magnetic field is a periodic magnetic field with a frequency of about 0.1 Hz.
52. The method of any one of claims 45 to 51, wherein the magnetic field is applied for at least about 2 hours a day.
53. The method of any one of claims 45 to 52, wherein the hydrogel is contacted with the wound for at least about 24 hours.
54. A magnetically responsive hydrogel of any one of claims 1 to 32, for use in treating a wound in a subject in need thereof, wherein the hydrogel is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
55. Use of a magnetically responsive hydrogel of any one of claims 1 to 32 in the manufacture of a medicament for treating a wound in a subject in need thereof, wherein the medicament is deformable in the presence of a magnetic field in order to stimulate one or more biological responses from the encapsulated cells.
Citation Information
Cited By
Magnetic hydrogel, preparation method thereof and non-invasive skin mechanical loading device
CN119455085A
An injectable hydrogel containing surface-modified PEG-PLGA nanoparticles loaded with bioactive substances for advanced wound healing
SE2530122A1
An injectable hydrogel containing surface-modified PEG-PLGA nanoparticles loaded with bioactive substances for advanced wound healing
SE548663C2
